

JC02 Rec'd PCT/PTO 01 APR 2002

TRANSMITTAL LETTER OF THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		Attorney Docket No. <b>0512-1030</b>
		U.S. Application No. <b>10/089612</b>
INTERNATIONAL APPLN. NO. <b>PCT/FR00/02596</b>	INTERNATIONAL FILING DATE <b>19 SEPTEMBER 2000</b>	PRIORITY DATE CLAIMED <b>1 OCTOBER 1999</b>
TITLE OF INVENTION: <b>PLANT SEED ENDOSPERM-SPECIFIC PROMOTERS</b>		
APPLICANT(S) FOR DE/EO/US: <b>JEAN-FRANCOIS BONELLO, PETER ROGOWSKY, PASCUAL PEREZ</b>		
Applicant herewith submits to the United States Designated Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau)</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau. See attached PCT/IB/308.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made, however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
<b>Items 11 to 20 below concern document(s) or information included:</b>		
<ol style="list-style-type: none"> <li>11. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS) w/PTO-1449 - <input checked="" type="checkbox"/> Copy of IDS citations</li> <li>12. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</li> <li>13. <input checked="" type="checkbox"/> A FIRST Preliminary Amendment.</li> <li>14. <input type="checkbox"/> A SECOND or SUBSEQUENT Preliminary Amendment.</li> <li>15. <input type="checkbox"/> A substitute specification.</li> <li>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule</li> <li>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>19. <input type="checkbox"/> A second copy of the English language translation of the international application (35 U.S.C. 154(d)(4)).</li> <li>20. <input checked="" type="checkbox"/> Other items or information: <b><u>International Search Report, PCT/IB/304, PCT/IPEA/409, Abstract of the Disclosure on a Separate Sheet, Application Data Sheet</u></b></li> </ol>		

JC10 Rec'd PCT/PTO 01 APR 2002

U.S. APPLICATION NO. <b>10/089612</b>		INTERNATIONAL APPLN. NO. PCT/FR00/02596		ATTORNEY DOCKET NO. 0512-1030	
21. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1)-(5):					
Neither international preliminary examination fee nor international search fee paid to USPTO and international Search Report not prepared by the EPO or JPO .....\$1040.00					
International preliminary examination fee not paid to USPTO but International Search Report prepared by the EPO or JPO .....\$890.00					
International preliminary examination fee not paid to USPTO but International search fee paid to USPTO .....\$740.00					
International preliminary examination fee paid to USPTO but all claims did not satisfy provision of PCT Article 33 (1)-(4) .....\$710.00					
International preliminary examination fee paid to USPTO and all claims satisfied provision of PCT Article 33 (1)-(4) .....\$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT</b>				\$ 890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20- <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e))				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	29 - 20 =	9	X \$18.00	\$ 162.00	
Independent Claims	20 - 3 =	17	X \$84.00	\$ 1,428.00	
MULTIPLE DEPEND CLAIM(S) (if applicable)			+ \$280.00	\$	
<b>TOTAL OF ABOVE CALCULATION -</b>				<b>\$ 2,480.00</b>	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+	
<b>SUBTOTAL =</b>				\$ 2,480.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492Z(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$ 2,480.00	
Fee for recording the enclosed assigned (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) \$40.00 per property +				\$	
<b>TOTAL FEES ENCLOSED -</b>				<b>\$ 2,480.00</b>	
				Amount to be refunded:	\$
				Charged:	\$
<input checked="" type="checkbox"/> A Check in the amount of <b>\$2,480.00</b> to cover all fees is attached.					
<input type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit account No. 25-0120 in the name of Young & Thompson, as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17.					
SEND ALL CORRESPONDENCE TO:					
745 South 23rd Street					
Arlington, VA 22202					
Telephone (703) 521-2297					
Y&T Customer No. 000466					
		SIGNATURE <u>Benoit Castel</u>			
		Benoit Castel			
		NAME			
		35,041			
		REGISTRATION NO.			
BC/ia					
Date: <b>April 1, 2002</b>					

10/089612

JC10 Rec'D T/PTO 01 APR 2002

**Application Data Sheet****Application Information**

Application Type:: Regular  
Subject Matter:: Utility  
Suggested Classification::  
Suggested Group Art Unit::  
CD-ROM or CD-R?: None  
Number of CD disks::  
Number of Copies of CDs::  
Sequence Submission?: None  
Computer Readable Form (CRF):: No  
Number of copies of CRF:: 0  
Title:: PLANT SEED ENDOSPERM-SPECIFIC  
PROMOTERS  
Attorney Docket Number:: 0512-1030  
Request for Early Publication?: No  
Request for Non-Publication?: No  
Suggested Drawing Figure::  
Total Drawing Sheets:: 11  
Small Entity?: No  
Latin Name::  
Variety Denomination Name::  
Petition Included?: No  
Petition Type::  
Licensed US Gov't Agency::  
Contract or Grant Numbers::  
Secrecy Order in Parent Appl.?: No

**Applicant Information**

Applicant Authority Type:: Inventor  
 Primary Citizenship Country:: FRANCE  
 Status:: Full Capacity  
 Given Name:: JEAN-FRANCOIS  
 Middle Name::  
 Family Name:: BONELLO  
 City of Residence:: BUSSY ST GEORGES  
 State or Province of Residence::  
 Country of Residence:: FRANCE  
 Street of Mailing Address:: 9 RUE J.MONET

City of Mailing Address:: BUSSY ST GEORGES  
 State or Province of Mailing Address::  
 Country of Mailing Address:: FRANCE  
 Postal or Zip Code of Mailing Address:: 77600

Applicant Authority Type:: Inventor  
 Primary Citizenship Country:: GERMANY  
 Status:: Full Capacity  
 Given Name:: PETER  
 Middle Name::  
 Family Name:: ROGOWSKY  
 City of Residence:: LYON  
 State or Province of Residence::  
 Country of Residence:: FRANCE  
 Street of Mailing Address:: 31 RUE ANDRE BOLLIER

City of Mailing Address:: LYON  
 State or Province of Mailing Address::  
 Country of Mailing Address:: FRANCE  
 Postal or Zip Code of Mailing Address:: 69007

Applicant Authority Type:: Inventor  
 Primary Citizenship Country:: FRANCE  
 Status:: Full Capacity  
 Given Name:: PASCUAL  
 Middle Name::  
 Family Name:: PEREZ  
 City of Residence:: CHANONAT  
 State or Province of Residence::  
 Country of Residence:: FRANCE  
 Street of Mailing Address:: 17 CHEMIN DE LA PRADELLE  
 VARENNES  
 City of Mailing Address:: CHANONAT  
 State or Province of Mailing Address::  
 Country of Mailing Address:: FRANCE  
 Postal or Zip Code of Mailing Address:: 63450

#### Correspondence Information

Correspondence Customer Number:: 000466

#### Representative Information

Representative Customer Number::	000466
----------------------------------	--------

#### Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This application	National Stage of	PCT/FR00/02596	9/19/00

**Foreign Priority Information**

Country::	Application Number::	Filing Date::	Priority Claimed::
FRANCE	99 12305	10/1/99	Yes

**Assignment Information**

Assignee Name::

Street of Mailing Address::

City of Mailing Address::

State or Province of Mailing Address::

Country of Mailing Address::

Postal or Zip Code of Mailing Address::

10089612 .091802

10/089612

IC10 Rec'd PCT/PTO 01 APR 2002

PATENT  
0512-1030

**IN THE U.S. PATENT AND TRADEMARK OFFICE**

In re application of: Jean-Francois BONELLO et al.

Appl. No.: **NEW** Group:

Filed: April 1, 2002 Examiner:

For: PLANT SEED ENDOSPERM-SPECIFIC PROMOTERS

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

April 1, 2002

Sir:

The following preliminary amendments and remarks are respectfully submitted in connection with the above-identified application.

**IN THE CLAIMS:**

Please cancel claims 1-16 without prejudice or disclaimer of the subject matter contained therein.

Please add the following claims:

--17. (new) An isolated promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm

surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm.--

--18. (new) A promoter nucleotide sequence according to claim 17, isolated from cereals.--

--19. (new) A promoter nucleotide sequence according to claim 17, isolated from maize.--

--20. (new) A promoter nucleotide sequence according to claim 17, comprising a sequence chosen from amongst the sequences SEQ ID N° 1, N° 2, N° 3, N° 4, N° 5, N° 6 and N° 7, and any sequence which is a homologue of these.--

--21. (new) A promoter nucleotide sequence according to claim 17, also comprising a regulator element in *cis* defined by the pattern CTACACCA.--

--22. (new) A promoter nucleotide sequence according to claim 17, also comprising a regulator element in *cis* defined by the pattern CTACACCA, repeated in tandem.--

--23. (new) An expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of the endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest.--



--24. (new) An expression cassette according to claim 23, in which the gene of interest codes for a protein is chosen from amongst a protein involved in the biological characteristics selected from the group consisting of the development of the embryo, the development of the endosperm, the cell growth, the metabolism of sugars, the metabolism of the fatty acids, the metabolism of a toxic protein and the metabolism of a transcription inhibiting protein.--

--25. (new) An expression cassette according to claim 23, in which the gene of interest codes for a first protein is chosen from amongst barnase and isopentenyltransferase.--

--26. (new) An expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest.--

--27. (new) An angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular

in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest.--

--28. (new) An angiosperm plant host cell in the form of cereal transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest.--

--29. (new) A transgenic plant, selected from the group consisting of fruit, seed, grain and pollen, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest.--

--30. (new) A part of a transgenic plant, selected from the group consisting of fruit, seed, grain and pollen, generated from

an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest.--

--31. (new) A transgenic plant, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, wherein the transgenic plant is a plant selected from the group consisting of a cereal, an oily plant, maize, wheat, rape and sunflower.--

--32. (new) A part of a transgenic plant selected from the group consisting of fruit, seed, grain and pollen, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding

sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, wherein the transgenic plant is a plant selected from the group consisting of a cereal, an oily plant, maize, wheat, rape and sunflower.--

--33. (new) A hybrid transgenic plant obtained by crossing parts of transgenic plants, each part of the transgenic plant being selected from the group consisting of fruit, seed, grain and pollen, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest.--

--34. (new) A hybrid transgenic plant obtained by crossing transgenic plants, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is

bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, wherein the transgenic plant is a plant selected from the group selected from a cereal, an oily plant, maize, wheat, rape and sunflower.--

--35. (new) A method of obtaining an angiosperm plant having improved agronomic or nutritional qualities, comprising the steps consisting of:

- transforming at least one angiosperm plant cell by means of an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest; and

- cultivating the cell thus transformed so as to generate a plant containing in its genome an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression

being i) specific to the region of the endosperm surrounding the embryo in the seeds of the angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest.--

--36. (new) Use of an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, said use of the expression cassette being for obtaining a transgenic angiosperm plant exhibiting improved agronomic qualities.--

--37. (new) Use of an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, said use of the expression cassette being for obtaining a transgenic angiosperm plant exhibiting improved nutritional qualities.--

--38. (new) Use according to claim 36, for obtaining a transgenic plant producing seeds selected from the group consisting of starch contents modified compared with a non-transformed plant.--

--39. (new) Use according to claim 36, for obtaining a transgenic plant producing seeds selected from the group consisting of oil contents modified compared with a non-transformed plant.--

--40. (new) Use of a plant, selected from the group consisting of a seed, grain and fruit, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, the plant being for the preparation of derived products, notably food products.--

--41. (new) Use of a plant, selected from the group consisting of a seed, grain and fruit, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i)

specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, the part of the plant being for the preparation of derived products, notably food products.--

--42. (new) Use of a transgenic plant, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, wherein the transgenic plant is a plant selected from the group consisting of a cereal, an oily plant, maize, wheat, rape and sunflower, the plant being for the preparation of derived products, notably food products.--

--43. (new) Use of a part of a transgenic plant, selected from the group comprising a seed, grain and fruit, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i)



specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, the plant being for the preparation of derived products, notably food products.--

--44. (new) Use of a part of a hybrid transgenic plant, selected from the group comprising a seed, grain and fruit, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, the plant being for the preparation of derived products, notably food products.--

--45. (new) Use of a hybrid transgenic plant, generated from an angiosperm plant host cell, transformed by an expression vector containing an expression cassette comprising an isolator promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound, the said expression being i) specific to the region of an endosperm surrounding an embryo in seeds of angiosperms and ii) intervening in particular in the

Docket No. 0512-1030

early stages of development of the endosperm, the expression cassette being effectively bound to at least one gene of interest, wherein the hybrid transgenic plant is a plant selected from the group comprising a cereal, an oily plant, maize, wheat, rape and sunflower, the plant being for the preparation of derived products, notably food products.--

Docket No. 0512-1030

REMARKS

Claims 17-45 are pending in the present application. Claims 1-16 have been cancelled and claims 17-45 have been added.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly requested.

Should there be any matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number listed below.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON



---

Benoit Castel, Reg. No. 35,041

745 South 23<sup>rd</sup> Street  
Arlington, VA 22202  
Telephone (703) 521-2297

BC/ia  
Attachments

Atty. Docket No. 0512-1030

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Jean-Francois BONELLO et al.

Confirmation No. 2604

Serial No. 10/089,612

BOX PCT

Filed April 1, 2002

PLANT SEED ENDOSPERM-SPECIFIC  
PROMOTERS

PRELIMINARY AMENDMENT

Commissioner for Patents

Washington, D.C. 20231

Sir:

Prior to the first Official Action, please amend the  
above-identified application as follows:

IN THE SPECIFICATION:

Replace the paragraph beginning at page 2, line 29,  
with the following rewritten paragraph:

--The promoter sequences of invention can  
advantageously be selected from the group consisting of the  
sequence comprising the sequences SEQ ID NO: 1, NO: 2, NO: 3, NO:  
4, NO: 5, NO: 6 or NO: 7 and any nucleotide sequence which is a  
homologue of these.--

Replace the paragraph beginning at page 3, line 1, with  
the following rewritten paragraph:

--The sequence SEQ ID NO: 1 corresponds to the gene  
promoter *Esrl*.--

BONELLO et al. S.N. 10/089,612

Replace the paragraph beginning at page 3, line 5, with the following rewritten paragraph:

--The sequence SEQ ID NO: 2 corresponds to the gene promoter *Esr2*.--

Replace the paragraph beginning at page 3, line 8, with the following rewritten paragraph:

--The sequence SEQ ID NO: 3 corresponds to the gene promoter *Esr3*.--

Replace the paragraph beginning at page 3, line 11, with the following rewritten paragraph:

--The sequence SEQ ID NO: 4 corresponds to the gene promoter *Esr4*.--

Replace the paragraph beginning at page 3, line 14, with the following rewritten paragraph:

--The sequence SEQ ID NO: 5 corresponds to a fragment of 499 pairs of bases on SEQ ID NO: 2 (nucleotides 1995-2493).--

Replace the paragraph beginning at page 3, line 17, with the following rewritten paragraph:

--The sequence SEQ ID NO: 6 corresponds to a fragment of 507 pairs of bases on SEQ ID NO: 3 (nucleotides 1202-1708).--

Replace the paragraph beginning at page 3, line 20, with the following rewritten paragraph:

--The sequence SEQ ID NO: 7 is a consensus sequence of 265 nucleotides, obtained by means of comparison between the sequences SEQ ID NO: 1, NO: 2 and NO: 3.--

BONELLO et al. S.N. 10/089,612

Replace the paragraph beginning at page 3, line 24, with the following rewritten paragraph:

--"Homologous nucleotide sequence" means any nucleotide sequence which differs from the sequence SEQ ID NO: 1, NO: 2, NO: 3, NO: 4, NO: 5, NO: 6 or NO: 7, by a substitution, deletion and/or insertion of one or more nucleotides, at positions such that these homologous nucleotide sequences preserve the property of specific promoter of the sequences SEQ ID NO: 1 to NO: 7.--

Replace the paragraph beginning at page 3, line 32, with the following rewritten paragraph:

--Preferably such a homologous nucleotide sequence is identical to at least 70% of the sequences SEQ ID NO: 1 to NO: 7, preferably at least 80%, preferably still at least 95%.--

Replace the paragraph beginning at page 4, line 18, with the following rewritten paragraph:

--Preferentially, such homologous nucleotide sequences specifically hybridises to the sequences which are complementary to the sequences SEQ ID NO: 1 to NO: 7 under stringent conditions. The parameters defining the stringency conditions depend on the temperature at which 50% of the paired strands separate ( $T_m$ ).--

Replace the paragraph beginning at page 5, line 9, with the following rewritten paragraph:

--The various nucleotide sequences of the invention can be of artificial origin or not. They may be DNA sequences

BONELLO et al. S.N. 10/089,612

obtained by sieving banks of sequences by means of sensors produced on the basis of the SEQ ID NO: 1 to NO: 7. Such banks can be prepared by conventional techniques of molecular biology, known to persons skilled in the art.--

Replace the paragraph beginning at page 13, line 9, with the following rewritten paragraph:

--Figure 9 shows a comparison of the sequences of the promoters of the genes *Esr1*, *Esr2* and *Esr3* (respectively prEsr1, prEsr2 and prEsr3, or residues 271 to 531 of SEQ ID NO: 1, residues 1992 to 2493 of SEQ ID NO: 2 and residues 1199 to 1708 of SEQ ID NO: 3), the preserved parts being aligned.--

Replace the paragraph beginning at page 14, line 25, with the following rewritten paragraph:

--As illustrated in Figure 1, fragments containing the open reading phases of *Esr1*, *Esr2* and *Esr3* (Opsahl et al., 1997) as well as upstream and downstream sequences were sub-cloned in the plasmid pBluescript SK+ (Stratagene) in accordance with the methods described in Sambrook et al. (1989). The result was the plasmid L23/7 containing a fragment Sall of 2.1 kb of  $\lambda$ Esr1g1 and the plasmid L33/1 containing a fragment BamHI of 3.4 kb of  $\lambda$ Esr2g1. The plasmid L33/10 containing a fragment BamHI of 1.9 kb of  $\lambda$ Esr2g1 and the plasmid L102c24 containing a fragment HindIII of 4.5 kb of  $\lambda$ E1-111. XbaI sites situated just upstream of the open reading phase (TCTAGATTCCATG) (SEQ ID NO: 22) made it

BONELLO et al. S.N. 10/089,612

possible to differentiate the putative promoters of the respective open reading phases. In particular, the fragment *SaII/XbaI* of 0.53 kb of L23/7 was designated as a putative promoter of *Esr1*, the fragment *HindIII/BamHI* of 2.35 kb of L33/1 (upstream part of the promoter) and the fragment *BamHI/XbaI* of 0.14 kb of L33/10 (downstream part of the promoter), that of the putative promoter of *Esr2*, the fragment *HindIII/XbaI* of 1.71 kb, that of the putative promoter of *Esr3* and the fragment *XbaI/XbaI* of 1.62 kb comprising the putative promoter of *Esr4*. A functional promoter *Esr2* of 2.49 kb was reconstructed from the fragment *HindIII/BamHI* of 2.35 kb of L33/1 and from the fragment *BamHI/XbaI* of 0.14 kb of L33/10, in a base plasmid of the pBSSK+ type (Stratagene). The orientation of the arrows in Figure 1 represents the orientation 5'-3'.--

Replace the paragraph beginning at page 16, line 4, with the following rewritten paragraph:

--The consensus sequence (SEQ ID NO: 7) was obtained after alignment of the three promoter nucleotide sequences and using Sequencher 3.1 software from Genes Codes Corporation (Ann Arbor, MI 48106).--

Replace the paragraph beginning at page 17, line 8, with the following rewritten paragraph:

--A homology is also observed between the proximal regions which extend over approximately 500 pairs of bases between the promoter of *Esr2* and that of *Esr3*, as defined by the



BONELLO et al. S.N. 10/089,612

sequences SEQ ID NO: 5 and NO: 6.--

Replace the paragraph beginning at page 19, line 5, with the following rewritten paragraph:

--\* the numbering of the promoter *Esr2* is based on the sequence p*Esr2* presented in an annexe (SEQ ID NO: 2) which goes from HindIII (AAGCTT or A = position 1) to XbaI (TCTAGA or A = position 2493).--

Replace the paragraph beginning at page 20, line 1, with the following rewritten paragraph:

--Secondly, fragments of the promoter were amplified using the initiator ESRX (5'GGGGTCTAGACTGTGAAGCTATTTTCCA3' (SEQ ID NO: 8)) containing the restriction site XbaI (underlined) and ESRH1 (5'GGGGAAGCTTTACATTCTTGCCATAACATA3' (SEQ ID NO: 9)), ESRH2 (5'GGGGAAGCTTTTCATCAATAATGCCTCATT3' (SEQ ID NO: 10)) or ESRH3 (5'GGGGAAGCTTTAATTCTTACTTCCTATCT3' (SEQ ID NO: 11)) containing the HindIII restriction site (underlined). The amplification products digested by XbaI and HindIII replaced the entire promoter *Esr2* upstream of the gene of the  $\beta$ -glucuronidase in the plasmid L124/19.--

Replace the paragraph beginning at page 20, line 13, with the following rewritten paragraph:

--The deleted promoters associated with the  $\beta$ -glucuronidase gene were then cloned in a plasmid containing the luciferase gene under the control of the promoter of the rice actin. The latter was obtained by cloning the fragment XhoI/NcoI

BONELLO et al. S.N. 10/089,612

of the plasmid pAct1-F4 (Mc Elroy D. et al., Mol Gen Genet., 231: 150-160, 1991) corresponding to the promoter and first intron of the rice actin, in a plasmid of the pGP214 type containing the luciferase gene and the terminator of nopaline synthase (Twell D. et al., Development 109, 705-713, 1990), digested by SalI/NcoI. An adaptor containing the restriction sites SalI and NotI, formed in nucleotides 5'GGCCAGTCGACAAAGCGGCCGCATGCA3' (SEQ ID NO: 12) and 5'TCAGCTGTTTCGCCGGCGT3' (SEQ ID NO: 13) was introduced into the plasmid obtained, digested by NotI and PstI (plasmid L210). The fragments SalI/NotI containing the deleted promoters associated with the  $\beta$ -glucuronidase gene were cloned in the plasmid L210 digested by SalI and NotI.--

Replace the paragraph beginning at page 23, line 8, with the following rewritten paragraph:

--<sup>1)</sup> adaptor JFB34:5'TCGACTGCAGCCCA 3' (SEQ ID NO: 14)

3'GACGTCGGGTTCGA 5' (SEQ ID NO: 15)

<sup>2)</sup> adaptor JFB56: 5'CTAGACCCGAATTCGC 3' (SEQ ID NO: 16)

3'TGGGCTTAAGCGCCGG 5' (SEQ ID NO: 17)--

Replace the paragraph beginning at page 27, line 19, with the following rewritten paragraph:

--In a plasmid derived from pJIT30 containing the promoter 35S, a multiple cloning site and the terminating sequence of the cabbage mosaic virus (Guerineau F. et al., Plant Mol Biol, 15: 127-136, 1990), an adaptor containing a SpeI site and formed by the oligonucleotides (5'GATCCACTAGTCCCG (SEQ ID NO:

BONELLO et al. S.N. 10/089,612

18)) and (5'AATTCGGGACTAGTG (SEQ ID NO: 19)) was inserted between the sites BamHI and EcoRI. The fragment EcoRI/SpeI of the plasmid L42 a14 (Opsahl-Ferstad et coll., 1997) was inserted in the plasmid described previously. The construction thus obtained contained the gene *Esr2* in antisense orientation under the control of the promoter 35S (plasmid L79 b5).--

Replace the paragraph beginning at page 28, line 8, with the following rewritten paragraph:

--The promoter 35S was eliminated in the plasmid L79 b5 by restriction by SacI and HindIII, and replaced by an adaptor containing the restriction site HindIII and NotI and formed by the oligonucleotides (5'AAGCTTTTTCGGCCGC (SEQ ID NO: 20)) and (5'TCGAGCGGCCGCAAAAAGCTTAGCT (SEQ ID NO: 21)). The promoter *Esr2* in the form of a fragment HindIII/NotI of 2.44 kb was introduced into this adaptor. The construction thus obtained contains the gene *Esr2* in antisense orientation under the control of its own promoter (plasmid L129/46 (cf Figure 11)).--

IN THE CLAIMS:

Amend claim 20 as follows:

20. (amended) A promoter nucleotide sequence according to claim 17, comprising a sequence chosen from amongst the sequences SEQ ID NO: 1, NO: 2, NO: 3, NO: 4, NO: 5, NO: 6 and NO: 7, and any sequence which is a homologue of these.

BONELLO et al. S.N. 10/089,612

REMARKS

The above changes in the specification and claims amend the present application so that it is commensurate in scope with the present Sequence Listing.

Attached hereto is a marked-up version of the changes made to the specification and claims. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

YOUNG & THOMPSON

By Philip A. DuBois  
Philip A. DuBois  
Agent for Applicants  
Registration No. 50,696  
745 South 23rd Street  
Arlington, VA 22202  
Telephone: 521-2297

September 18, 2002

BONELLO et al. S.N. 10/089,612

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

IN THE SPECIFICATION:

Paragraph beginning at page 2, line 29, has been amended as follows:

The promoter sequences of invention can advantageously be selected from the group consisting of the sequence comprising the sequences SEQ ID [N° 1, N° 2, N° 3, N° 4, N° 5, N° 6 or N° 7] NO: 1, NO: 2, NO: 3, NO: 4, NO: 5, NO: 6 or NO: 7 and any nucleotide sequence which is a homologue of these.

Paragraph beginning at page 3, line 1, has been amended as follows:

The sequence SEQ ID [N°] NO: 1 corresponds to the gene promoter *Esr1*.

Paragraph beginning at page 3, line 5, has been amended as follows:

The sequence SEQ ID [N°] NO: 2 corresponds to the gene promoter *Esr2*.

Paragraph beginning at page 3, line 8, has been amended as follows:

The sequence SEQ ID [N°] NO: 3 corresponds to the gene promoter *Esr3*.

Paragraph beginning at page 3, line 11, has been amended as follows:

The sequence SEQ ID [N°] NO: 4 corresponds to the gene

BONELLO et al. S.N. 10/089,612

promoter *Esr4*.

Paragraph beginning at page 3, line 14, has been amended as follows:

The sequence SEQ ID [N°] NO: 5 corresponds to a fragment of 499 pairs of bases on SEQ ID [N°] NO: 2 (nucleotides 1995-2493).

Paragraph beginning at page 3, line 17, has been amended as follows:

The sequence SEQ ID [N°] NO: 6 corresponds to a fragment of 507 pairs of bases on SEQ ID [N°] NO: 3 (nucleotides 1202-1708).

Paragraph beginning at page 3, line 20, has been amended as follows:

The sequence SEQ ID [N°] NO: 7 is a consensus sequence of 265 nucleotides, obtained by means of comparison between the sequences SEQ ID [N° 1, N° 2 and N° 3] NO: 1, NO: 2 and NO: 3.

Paragraph beginning at page 3, line 24, has been amended as follows:

"Homologous nucleotide sequence" means any nucleotide sequence which differs from the sequence SEQ ID [N° 1, N° 2, N° 3, N° 4, N° 5, N° 6 or N° 7] NO: 1, NO: 2, NO: 3, NO: 4, NO: 5, NO: 6 or NO: 7, by a substitution, deletion and/or insertion of one or more nucleotides, at positions such that these homologous nucleotide sequences preserve the property of specific promoter of the sequences SEQ ID [N° 1 to N° 7] NO: 1 to NO: 7.



promoters of the genes *Esr1*, *Esr2* and *Esr3* (respectively prEsr1, prEsr2 and prEsr3, or [SEQ ID N° 1, SEQ ID N° 2, and SEQ ID N° 3] residues 271 to 531 of SEQ ID NO: 1, residues 1992 to 2493 of SEQ ID NO: 2 and residues 1199 to 1708 of SEQ ID NO: 3), the preserved parts being aligned.

Paragraph beginning at page 14, line 25, has been amended as follows:

As illustrated in Figure 1, fragments containing the open reading phases of *Esr1*, *Esr2* and *Esr3* (Opsahl et al., 1997) as well as upstream and downstream sequences were sub-cloned in the plasmid pBluescript SK+ (Stratagene) in accordance with the methods described in Sambrook et al. (1989). The result was the plasmid L23/7 containing a fragment Sall of 2.1 kb of  $\lambda$ Esr1g1 and the plasmid L33/1 containing a fragment BamHI of 3.4 kb of  $\lambda$ Esr2g1. The plasmid L33/10 containing a fragment BamHI of 1.9 kb of  $\lambda$ Esr2g1 and the plasmid L102c24 containing a fragment HindIII of 4.5 kb of  $\lambda$ E1-111. XbaI sites situated just upstream of the open reading phase (TCTAGATTCCATG) (SEQ ID NO: 22) made it possible to differentiate the putative promoters of the respective open reading phases. In particular, the fragment SaII/XbaI of 0.53 kb of L23/7 was designated as a putative promoter of *Esr1*, the fragment HindIII/BamHI of 2.35 kb of L33/1 (upstream part of the promoter) and the fragment BamHI/XbaI of 0.14 kb of L33/10 (downstream part of the promoter), that of the putative promoter of *Esr2*, the fragment HindIII/XbaI of 1.71 kb,



BONELLO et al. S.N. 10/089,612

that of the putative promoter of *Esr3* and the fragment *XbaI/XbaI* of 1.62 kb comprising the putative promoter of *Esr4*. A functional promoter *Esr2* of 2.49 kb was reconstructed from the fragment *HindIII/BamHI* of 2.35 kb of L33/1 and from the fragment *BamHI/XbaI* of 0.14 kb of L33/10, in a base plasmid of the pBSSK+ type (Stratagene). The orientation of the arrows in Figure 1 represents the orientation 5'-3'.

Paragraph beginning at page 16, line 4, has been amended as follows:

The consensus sequence (SEQ ID [N°] NO: 7) was obtained after alignment of the three promoter nucleotide sequences and using Sequencher 3.1 software from Genes Codes Corporation (Ann Arbor, MI 48106).

Paragraph beginning at page 17, line 8, has been amended as follows:

A homology is also observed between the proximal regions which extend over approximately 500 pairs of bases between the promoter of *Esr2* and that of *Esr3*, as defined by the sequences SEQ ID [N° 5 and N° 6] NO: 5 and NO: 6.

Paragraph beginning at page 19, line 5, has been amended as follows:

\* the numbering of the promoter *Esr2* is based on the sequence p*Esr2* presented in an annexe (SEQ ID [N°] NO: 2) which goes from *HindIII* (AAGCTT or A = position 1) to *XbaI* (TCTAGA or A = position 2493).

Paragraph beginning at page 20, line 1, has been amended as follows:

Secondly, fragments of the promoter were amplified using the initiator ESRX (5'GGGGTCTAGACTGTGAAGCTATTTTCCA3' (SEQ ID [N°] NO: 8)) containing the restriction site XbaI (underlined) and ESRH1 (5'GGGGAAGCTTTACATTCTTGCCATAACATA3' (SEQ ID [N°] NO: 9)), ESRH2 (5'GGGGAAGCTTTTCATCAATAATGCCTCATT3' (SEQ ID [N°] NO: 10)) or ESRH3 (5'GGGGAAGCTTTAATTTCTTACTTCCTATCT3' (SEQ ID [N°] NO: 11)) containing the HindIII restriction site (underlined). The amplification products digested by XbaI and HindIII replaced the entire promoter *Esr2* upstream of the gene of the  $\beta$ -glucuronidase in the plasmid L124/19.

Paragraph beginning at page 20, line 13, has been amended as follows:

The deleted promoters associated with the  $\beta$ -glucuronidase gene were then cloned in a plasmid containing the luciferase gene under the control of the promoter of the rice actin. The latter was obtained by cloning the fragment XhoI/NcoI of the plasmid pAct1-F4 (Mc Elroy D. et al., Mol Gen Genet., 231: 150-160, 1991) corresponding to the promoter and first intron of the rice actin, in a plasmid of the pGP214 type containing the luciferase gene and the terminator of nopaline synthase (Twell D. et al., Development 109, 705-713, 1990), digested by SalI/NcoI. An adaptor containing the restriction sites SalI and NotI, formed in nucleotides 5'GGCCAGTCGACAAAGCGCCGCATGCA3' (SEQ ID [N°] NO:

12) and 5'TCAGCTGTTTCGCCGGCGT3' (SEQ ID [N°] NO: 13) was introduced into the plasmid obtained, digested by NotI and PstI (plasmid L210). The fragments SalI/NotI containing the deleted promoters associated with the  $\beta$ -glucuronidase gene were cloned in the plasmid L210 digested by SalI and NotI.

Paragraph beginning at page 23, line 8, has been amended as follows:

<sup>1)</sup> adaptor JFB34:5'TCGACTGCAGCCCA 3' (SEQ ID [N°] NO: 14)

3'GACGTCGGGTTCGA 5' (SEQ ID [N°] NO: 15)

<sup>2)</sup> adaptor JFB56: 5'CTAGACCCGAATTCGC 3' (SEQ ID [N°] NO: 16)

3'TGGGCTTAAGCGCCGG 5' (SEQ ID [N°] NO: 17)

Paragraph beginning at page 27, line 19, has been amended as follows:

In a plasmid derived from pJIT30 containing the promoter 35S, a multiple cloning site and the terminating sequence of the cabbage mosaic virus (Guerineau F. et al., Plant Mol Biol, 15: 127-136, 1990), an adaptor containing a SpeI site and formed by the oligonucleotides (5'GATCCACTAGTCCCG (SEQ ID [N°] NO: 18)) and (5'AATTCGGGACTAGTG (SEQ ID [N°] NO: 19)) was inserted between the sites BamHI and EcoRI. The fragment EcoRI/SpeI of the plasmid L42 a14 (Opsahl-Ferstad et coll., 1997) was inserted in the plasmid described previously. The construction thus obtained contained the gene *Esr2* in antisense orientation under the control of the promoter 35S (plasmid L79 b5).

Paragraph beginning at page 28, line 8, has been amended as follows:

The promoter 35S was eliminated in the plasmid L79 b5 by restriction by SacI and HindIII, and replaced by an adaptor containing the restriction site HindIII and NotI and formed by the oligonucleotides (5'AAGCTTTTTCGCGCCGC (SEQ ID [N°] NO: 20)) and (5'TCGAGCGCCGCAAAAAGCTTAGCT (SEQ ID [N°] NO: 21)). The promoter *Esr2* in the form of a fragment HindIII/NotI of 2.44 kb was introduced into this adaptor. The construction thus obtained contains the gene *Esr2* in antisense orientation under the control of its own promoter (plasmid L129/46 (cf Figure 11)).

IN THE CLAIMS:

Claim 20 has been amended as follows:

20. (amended) A promoter nucleotide sequence according to claim 17, comprising a sequence chosen from amongst the sequences SEQ ID [N° 1, N° 2, N° 3, N° 4, N° 5, N° 6 and N° 7] NO: 1, NO: 2, NO: 3, NO: 4, NO: 5, NO: 6 and NO: 7, and any sequence which is a homologue of these.

SEQUENCE LISTING

<110> BONELLO, JEAN-FRANCOIS  
ROGOWSKY, PETER  
PEREZ, PASCUAL

<120> PLANT SEED ENDOSPERM-SPECIFIC PROMOTERS

<130> 0512-1030

<140> 10/089,612

<141> 2002-04-01

<150> FR 99 12305

<151> 1999-10-01

<150> PCT/FR00/02596

<151> 2000-09-19

<160> 22

<170> PatentIn Ver. 2.1

<210> 1

<211> 531

<212> DNA

<213> Zea mays

<400> 1

gatcattaag	gactaagcag	tctttttccc	tttcggcttg	catcatcttt	agtcttcac	60
actattataa	gccgaagcta	ttacccttg	gctatagctt	cggtgttcac	ctttattatc	120
ttcggactat	gtcttcacct	tgtatacctt	tgtcttgggg	gaaaaccttc	atcctgaagc	180
cgaagctccc	tgtaataaatt	catatcatgc	taaaaataaa	tggtcagtc	tgtttttgag	240
gaccttcgga	agaggaaggc	cccccaacaa	gacgattaac	tagtattgtc	tcactgcatt	300
gttttttttg	cacttcacat	ataatgcctc	aatagcatac	ttcatttttag	gaactttatt	360
aaaactgtct	taaaataggg	ccaagtcata	aattcattca	aagtgactct	tcattttctta	420
cttcttatct	ttggtgggtt	tgtatatata	tatgttcacg	gttgagtgat	gttccctacac	480
cactacacca	cacgttagat	atatatacac	aaaatagctt	cactatctag	a	531

<210> 2

<211> 2493

<212> DNA

<213> Zea mays

<400> 2

aagcttttcc	ggtgatgaag	cacctgtaat	acttaacagc	atgctgaaaa	caaatagtta	60
gctgtgtttt	tgaggacctt	cggaagatga	aggcccccaa	cacatcccat	gcatcaagtc	120
cccatgactt	gcaaaaaagc	aaattttatc	aaaattttct	ataaaaacact	tgaaaacatt	180
tctctttttg	aaaagtgtag	agcactagca	actgtctact	aaaaagggtc	ccaaattttc	240
gggtataaca	atcgcattgg	aaataacaca	aaggaaatcc	tactaagagc	agtaatttgg	300
ctaaaaaca	agtgcatt	ttaatgtaat	agggaatagg	agcatgcaat	acttgtgttc	360
tttcagggtt	ttgatgtcct	caaaaagtgtg	ccccctggg	gcagttgcaa	cactcaaaat	420
ctactcgtat	acataaagaa	acatgggcac	aaaataagaa	acaatactca	aattatgaaa	480
aaggttcaaa	tggtccctata	attattgtag	acatttttaga	atttatttta	gaccaaaacc	540
atttaaattt	ggtttaaaaa	gagtttagata	ttaatattta	ttcagtttat	agttatttgg	600
gacattttatt	tacttaacta	taacttctag	ggttttaaaa	gtaaattttg	ggtccctagt	660
tggaactagc	tcagattgct	ggttgatttc	cataaaaagtc	gaggttcctt	tagcaaaaat	720

ccacggtgaa	caagggggag	ataggtgttg	accgatatct	ctaaatthttg	atcgttggac	780
ggcacatgga	tgtctcagat	taaatggtgg	atgtgcaagc	gacgcgcaca	cgatggagga	840
atggcttcac	gacggtgggc	tactagagct	ggctacgtca	accaatggag	ggctcgggtca	900
aggtcaaaat	ttgttgccaa	gccactgtgg	ctcacgatga	gtcgattgag	cacatatcaa	960
ggtcgagggg	caaccagagg	ggcaagatcg	atgggtgcagt	gggtgtctcg	atggaagggg	1020
aaacttcggg	gagcaattca	agatttccta	tcattgtgacc	gggtcaggga	atgggcgcac	1080
gggttttggg	accttctggg	gcacatcatg	ttgctgtatc	gatgtcaagg	gagcattagg	1140
gttcacgagt	cagcgatgac	gggcatgggt	ggacttgtgt	caccatgggt	cgatcaacta	1200
gggacgatag	agctctatga	agtttcacaa	cttcctcaca	ctctagggat	catgggtgaca	1260
aaggtgggga	ggacggggcg	tctctagtga	gggtggaatg	cagttctgtc	acgtgggaat	1320
agtggcggca	tcgcttgtaa	tgaataaaaag	gtgcttgggt	ggctgggaag	tgcaatatga	1380
gggaagtagt	tgggtgcgggg	atgttccttt	tataaggag	caccattgat	taatggaaga	1440
caatgacaca	aagggtgggt	cgacagttta	aagctcgaat	gctgctaggg	gtgctcaagg	1500
ttaaaagatc	aggcatcagg	gaggaaaggc	agggataaaa	tttctttact	ccagttgtgg	1560
ggtgatgggg	acaagggtag	tgctcaagca	agggaggggc	agttcagcgc	agagatgcct	1620
gttgtgacac	atgggggggg	gggaattgga	gggtgggggt	gaccagggtga	cgttatggcg	1680
tgaccagag	aagagaccca	ctgatgggga	aaaaagggtgc	caacagggtg	ggaccaagggt	1740
gtcagtgaact	caccgtgaca	tgttattgga	aagttacgtc	cggaatgggt	tgggcctgag	1800
tgatctaggc	tggctcgggc	actgtgctga	tcctttaatt	tctccattcc	caatttaagt	1860
tgaattttta	attcaaatca	aatgactcca	aatctctcca	aaattaccaa	aatatagaat	1920
atthagatga	atatgttggg	ggagtttggg	ctccgctttt	ggtagtatg	tttgtataaa	1980
aataatttct	ctccttttgt	cacttccaat	attgacttaa	atthttatgt	agcaatgcca	2040
acttttttta	gtagtgtgcc	acttatagca	caaaaactat	atccattttc	taatagtcct	2100
tgaaatccac	attctatttt	tagccattct	tcaaaattgg	cacaaaacta	ggaaaattta	2160
atacattctt	gccataacat	attctagtgc	aaatgttaac	tagattgtct	aatattagca	2220
aacttctttt	gtaagattca	ttaatatgtc	tacattgcat	acttttttag	aagttcatca	2280
ataatgctc	attagcatac	ttcattttag	gaacttgatt	aaaaccgcct	taaaatagag	2340
ccaagtgcg	gatccattta	aagggtgattc	ttaatttctt	acttcctatc	tttgggtggc	2400
tatgtttata	tatgtgtggg	tgggtgaatg	atgttctctac	accactacac	cacacgttgg	2460
acatatatat	ggaaaatagc	ttcacagtct	aga			2493

<210> 3  
 <211> 1708  
 <212> DNA  
 <213> Zea mays

<400> 3						
aagcttagaa	atthttaaaa	aagccaggca	agcgttgggtg	tgcaaagagc	taaaaattag	60
gaagacaaga	gaacacggca	agaaagcatg	ctaaatgtgc	tcgcggtgcg	ttcttattta	120
tacgctcaat	acgttgcaag	tggtagggcc	ccacttgtca	ttgactattg	ctattctagc	180
aaaggggaag	tgthtttcgg	accttcggct	taaggccttc	gtccatatcg	caatctgaat	240
ttatcattct	aacaaattaa	tattgtgagg	ggctactgtt	gggggccttc	gacttccgaa	300
ggctctcaaa	aactgggtta	acagtgtttc	tggagtataa	tgcataaaca	ggtatcttcg	360
ggtttgatc	agaactacaa	catgaagagg	cacaaagaac	acgaagggtg	gcgcagagcc	420
gaagctcacg	tgtaggagag	cttcggcacg	acagcagaaa	aagggaaccg	acttaaaagg	480
aaaggctatt	cagacctcga	tggatttcta	taggtcatta	gcaaatgtaa	agggcattgaa	540
tgtaatttta	catgggctgt	gtccttgcc	ataaatagat	gaacagtact	ctcgtactgt	600
tcacgctgac	ttggcattcg	ctthttgcat	cacgttgtga	cccttgcttt	ccttcaaac	660
gaaggtacat	ctataatttg	ttattgtgtt	attgtggata	tggtaatgca	aataaaaaata	720
agttgatgat	aatgtttata	ttatttttcg	tatttcata	atgaattctt	cctcatcatt	780
tattgtgctt	acgaagggtt	ttccttcaaa	atctttgtcc	ggaattcatt	atatccgaag	840
ggaaataatg	tctcgaagga	cgaaggactt	tgatatttaa	cacttttcat	gttgccttgt	900
tcttgactct	tagcatttga	gaacaagtcc	ccaacagctc	ctaagctctt	ctttgaagaa	960
acaactacta	gatgaagttt	ctccaaaagt	acgtccattg	aatggagtaa	agagtcattt	1020
gacctctcgg	aataaaaatta	aaatgagaat	aagtaagaat	aaaacacctc	tattatcaaa	1080
tctaggccat	acaaacattg	ggtattacta	aaaatatagc	aatgccatct	ttcaaacatt	1140
ggaagttaaa	accaaccaat	cctcactcat	tccaagaaa	tattggatca	tatttaacat	1200

3

tttgtgtcac	ttacaaaaat	ggcttaatct	tttatgcggc	aatgccaaac	tttttttagca	1260
gggtgccact	tgtaacatga	aaactataac	tatttttcaaa	tagtaccttg	aaattcgcat	1320
tctattttta	tgcatctctc	aaaattgaca	caaattaaac	taggagaatt	caatacatctc	1380
ttgccataac	atattctaata	gcaaataatta	agtagattgc	tcaacatcgg	tacacatctt	1440
ttggacgatt	aattagtatt	gtctcactac	attctttgtt	ttagcagttc	atcaataatg	1500
cctcaatagc	atacttcatt	ttaggaactt	tatgaaaatt	gtcttaaaat	agggccaagt	1560
cacaaatcca	cttcaaaggt	gactcttcac	ttcttacttc	ctatctttgc	ttgtttttgt	1620
atatatatgt	gtggatgggt	gagtgatgtt	cctacaccac	tacaccacac	cttagacaca	1680
tatatggaaa	atagcttcac	tgtctaga				1708

<210> 4  
 <211> 1232  
 <212> DNA  
 <213> Zea mays

<400> 4						
tagttcatgc	aaaagtagtg	agtgtttata	cacctatgcc	aatgaataac	ctctaactac	60
cctcatgtac	tggcctgggtg	tttggtaaac	atgaagcaat	aatttcctct	tatcaaaata	120
cgggtctcaa	gctgcatgtg	aaaaataata	aatatTTTTT	tgaagtgaat	gaaaaatgat	180
aaatatgaaa	cagtaaactct	ttccgttgaa	aaagtacatc	tctattatta	acgataacct	240
atatatcaat	ctacaatgcg	ctcatctgca	tctcgatgca	tactttcatc	atTTTTatgaa	300
tgtacttttaa	tgataagaag	gattagaatg	ttcttgTTTT	cctcttattc	ttacctTTTT	360
caaaattatc	agtttccaat	gtctgaatat	gcaatgcatt	ataaacctta	gtcagcatat	420
atcaagtoga	tatatataatgc	tatatgttta	agaactgggtg	ctgagtatgt	ctactcaaca	480
tatttttttag	ctattggatc	gagcagttta	gtaaaggtaa	actacattta	tctatcttca	540
agttgtattt	tcccaccctt	aaattatgaa	agggagtaac	gtccactcc	aactgttgaa	600
agggaaacaaa	tttggctctcc	ggactgattt	cattgggtgg	tctctatttt	ttaaaaaac	660
aaaaaaacat	atttgttctc	tgaaaattga	taattaatta	atcataaatt	aggaaaaaaa	720
ctatatgaaa	ctagttatag	ttttcttcta	aaattattgt	ctgtctgttg	gtgctctagt	780
tatagagtta	taacatgaaa	actatagcca	ttttcaaaata	gtgccttgaa	attcattttt	840
gttttagccat	tcttcaaaat	tgccacccaaa	ccaggagaat	ttattaataa	attcacgcca	900
taacatatctc	tagtccaaat	gttaagtggg	ttgctcaata	tcattatact	tcttttggac	960
gattcatttag	tactgccttg	ttgcataactt	gttttttagca	gttcatcaat	aatgcttcac	1020
tagcataatt	catgttagga	acttgattaa	aactgcctta	agaacatggc	aaagtgataa	1080
atccacttca	aaggcaatta	ttaatTTCTT	acttctctatc	tttgggtgggt	tttgtatata	1140
tgtgtgtggg	tggttgagtg	atgcacacat	tttctacac	cactacatca	caccttggac	1200
atatatgtga	aaaaatagct	tcgcagtcta	ga			1232

<210> 5  
 <211> 499  
 <212> DNA  
 <213> Zea mays

<400> 5						
tttgtcact	tccaatattg	acttaaaattt	ttatgtagca	atgccaaactt	tttttagtag	60
tgtgccactt	atagcacaaa	aactatatcc	atTTTtcta	agtcccttgaa	atccacattc	120
tatTTTTtagc	cattcttcaa	aattggcaca	aaactaggaa	aatttaatac	attcttgcca	180
taacatatctc	tagtgcaaat	gttaactaga	ttgctcaata	ttagcaaaact	tcttttgtaa	240
gattcattaa	tattgctaca	ttgcataactt	ttttagaagt	tcatcaataa	tgccctcatta	300
gcatacttca	tttttaggaac	ttgattaaaa	ccgccttaaa	atagagccaa	gtgacggatc	360
catttaaagg	tgattcttaa	tttcttactt	cctatctttg	gtggcttatg	tttatatatg	420
tgtgggtggg	tgaatgatgt	tcctacacca	ctacaccaca	cgttggacat	atatatggaa	480
aatagcttca	cagtctaga					499

4

<210> 6  
<211> 507  
<212> DNA  
<213> Zea mays

<400> 6  
ttgtgtcact tacaaaaatg gcttaatctt ttatgcggca atgccaacct ttttttagcag 60  
ggtgccactt gtaacatgaa aactataact attttcaaag agtaccttga aattcgcat 120  
ctatttttat gcattcttca aaattgacac aaattaaact aggagaattc aatacattct 180  
tgccataaca tatttctaag caaatattaa gtagattgct caacatcggt acacatcttt 240  
tggaagatta attagtattg tctcactaca ttctttggtt tagcagttca tcaataatgc 300  
ctcaatagca tacttcattt taggaacttt atgaaaattg tcttaaaata gggccaagtc 360  
acaaatccac ttcaaagggt actcttcatt tcttacttcc tatctttgct tgtttttgta 420  
tatatatgtg tggatggtg agtgatgttc ctacaccact acaccacacc ttagacacat 480  
atatggaaaa tagcttcact gtctaga 507

<210> 7  
<211> 265  
<212> DNA  
<213> Zea mays

<220>  
<221> modified\_base  
<222> (1)  
<223> a, c, t, g, other or unknown

<220>  
<221> modified\_base  
<222> (32)  
<223> a, c, t, g, other or unknown

<220>  
<221> modified\_base  
<222> (35)  
<223> a, c, t, g, other or unknown

<220>  
<221> modified\_base  
<222> (128)  
<223> a, c, t, g, other or unknown

<220>  
<221> modified\_base  
<222> (136)  
<223> a, c, t, g, other or unknown

<220>  
<221> modified\_base  
<222> (175)  
<223> a, c, t, g, other or unknown

<400> 7  
namgattmay tartattggy wcaytreatw snttnttttr gmasttcatc aataatgcct 60  
cawtagcata cttcatctta ggaacttkat kaaaaygyt ttaaaatagr gccaagtsay 120  
rratycantt yaaagntgay tcttmatttc ttacttecta tctttgstkg yttwngtwt 180  
tatatrtgtk srtggtgar tgatgttctt acaccactac accacacstt rgayayatat 240  
ayrgaaaata gcttcacwrt ctaga 265



<210> 8  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 8  
ggggtctaga ctgtgaagct attttcca

28

<210> 9  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 9  
ggggaagctt tacattcttg ccataacata

30

<210> 10  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 10  
ggggaagctt ttcataata atgcctcatt

30

<210> 11  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 11  
ggggaagctt taatttctta cttcctatct

30

<210> 12  
<211> 27  
<212> DNA  
<213> Artificial Sequence



<400> 16  
ctagacccga attcgc 16

<210> 17  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 17  
ggccgcgaat tcgggt 16

<210> 18  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 18  
gatccactag tcccg 15

<210> 19  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 19  
aattcgggac tagtg 15

<210> 20  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 20  
aagctttttg cggccgc 17

<210> 21  
<211> 25

8

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 21  
tcgagcggcc gcaaaaagct tagct 25

<210> 22  
<211> 13  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 22  
tctagattcc atg 13

ii/p/r/r/s

1

JC10 Rec'd PCT/PTO 01 APR 2002

The present invention relates to controlling the expression of genes during the development of the endosperm. It concerns in particular promoter nucleotide sequences which enable expression which is both specific to the interface between the embryo and the endosperm and early during the development of the endosperm.

10

The endosperm, a characteristic formation of Angiosperm seeds, is a nutritive tissue for the embryo. This is a tissue which is complex in its structure and development, in particular with cereals. The central area of the endosperm consists of large cells with vacuoles, which store the reserves of starch and proteins, whilst the region surrounding the embryo is distinguished by rather small cells, occupied for the major part by cytoplasm. At the present time the function of these cells, referred to as "dense cytoplasmic cells" (Schel et al. 1984) is not known. In 1994 Opsahl et al. identified a gene expressed specifically in this small region around the maize embryo, a gene which they called *Esr* standing for "Embryo Surrounding Region".

25

The authors of the present invention have now isolated promoter nucleotide sequences enabling an expression of the coding sequences with which they can be bound, which is specific to the region of the endosperm surrounding the embryo in Angiosperm seeds and which intervenes particularly in the early stages of the development of the endosperm.

Such promoter sequences are particularly useful for targeting or regulating the expression of genes of interest.

5 In the context of an improvement to plants by transgenesis, a promoter nucleotide sequence of this type can be bound effectively to a coding sequence for a gene of interest.

10 The nucleotide construction, preferably inserted in a vector, can be used for transforming plant cells in a stable fashion, so that the plant thus transformed contains in its genome the gene of interest associated with the promoter sequence of the invention.

15 The seeds which grow, by fertilisation, from this plant also contain this transgene in their genome.

20 Because of its association with the promoter sequence of the invention, this transgene of interest will be expressed only in the region of the endosperm surrounding the embryo, that is to say in the dense cytoplasmic cells as mentioned above.

25 The expression of the transgene begins from the very first days after pollination, more precisely as from the fourth day after pollination.

30 The promoter sequences of invention can advantageously be selected from the group consisting of the sequences comprising the sequences SEQ ID N° 1, N° 2, N° 3, N° 4, N° 5, N° 6 or N° 7 and any nucleotide sequence which is a homologue of these.

The sequence SEQ ID N° 1 corresponds to the gene promoter *Esr1*.

5 The sequence SEQ ID N° 2 corresponds to the gene promoter *Esr2*.

The sequence SEQ ID N° 3 corresponds to the gene promoter *Esr3*.

10

The sequence SEQ ID N° 4 corresponds to the gene promoter *Esr4*.

15 The sequence SEQ ID N° 5 corresponds to a fragment of 499 pairs of bases on SEQ ID N° 2 (nucleotides 1995-2493).

The sequence SEQ ID N° 6 corresponds to a fragment of 507 pairs of bases on SEQ ID N° 3 (nucleotides 1202-1708).

20 The sequence SEQ ID N° 7 is a consensus sequence of 265 nucleotides, obtained by means of comparison between the sequences SEQ ID N° 1, N° 2 and N° 3.

25 "Homologous nucleotide sequence" means any nucleotide sequence which differs from the sequence SEQ ID N° 1, N° 2, N° 3, N° 4, N° 5, N° 6 or N° 7, by a substitution, deletion and/or insertion of one or more nucleotides, at positions such that these homologous nucleotide sequences preserve the property of specific promoter of the sequences SEQ ID  
30 N° 1 to N° 7.

Preferably such a homologous nucleotide sequence is identical to at least 70% of the sequences SEQ ID N° 1 to

Homology is generally determined using a sequence analysis software (for example, the Sequence Analysis Software package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Similar nucleotide sequences are aligned in order to obtain the maximum degree of homology (i.e. identity). To this end, it may be necessary to artificially introduce gaps in the sequence. Once the optimum alignment has been achieved, the degree of homology (i.e. identity) is established by recording all the positions for which the nucleotides of the two compared sequences are identical, with respect to the total number of positions.

25 For sequences comprising more than 30 bases,  $T_m$  is defined  
by the equation:  $T_m = 81.5 + 0.41 (\% G + C) + 16.6 \log$   
(concentration in cations) - 0.63 (%formamide) -  
(600/number of bases) (Sambrook et al., Molecular Cloning,  
A Laboratory Manual, Coldspring Harbor Laboratory Press,  
30 1989, pages 9.54-9.62).

For sequences with a length less than 30 bases,  $T_m$  is defined by the equation:  $T_m = 4(G + C) + 2(A + T)$ .



Under appropriate stringency conditions, to which the aspecific sequences do not hybridise, the hybridisation temperature is approximately 5° to 30°C, preferably 5° to 10°C below T<sub>m</sub>, and the hybridisation buffers used are preferably solutions with a ionic strength such as a 6xSSC solution for example.

The various nucleotide sequences of the invention can be of artificial origin or not. They may be DNA sequences obtained by sieving banks of sequences by means of sensors produced on the basis of the SEQ ID N° 1 to N° 7. Such banks can be prepared by conventional techniques of molecular biology, known to persons skilled in the art.

The nucleotide sequences according to the invention can also be prepared by chemical synthesis, or by mixed methods including the chemical or enzymatic modification of sequences obtained by sieving banks.

The promoter nucleotide sequences of the invention are preferably sequences isolated from cereals, in particular maize.

The promoter nucleotide sequences according to the present invention can in particular be isolated by methods of reversed PCR or working on the genome (Devic et al., 1997).

The promoter nucleotide sequences of the invention can also comprise or be associated with a *cis* CTACACCA regulating pattern, preferably repeated in tandem, or any



The gene of interest can be placed in sense or antisense orientation.

5 The promoter nucleotide sequence of the invention can also be associated with a marker gene, for example a gene making it possible to select a plant transformed from a plant which does not contain transfected foreign DNA. As a marker gene, it is possible to cite in particular a gene confirming resistance to an antibiotic (Herrera-Estrella  
10 et al., EMBO J. 2, 987-995 (1983)) or resistance to a herbicide (EP 242 246).

Another object of the invention is any nucleotide vector, such as a plasmid, which can be used for transforming host  
15 cells, characterised in that it comprises an expression cassette as defined above. The construction of expression vectors for the transformation is within the capability of one skilled in the art following standard techniques.

20 Another object of the invention is an Angiosperm plant host cell, notably a cereal, transformed by a vector according to the invention.

The invention also concerns a transgenic plant or part of  
25 a transgenic plant, in particular seed, fruit or pollen, generated from such a cell.

Amongst the cells able to be transformed according to the method of the invention, examples are cells of extensively  
30 farmed plants (maize, wheat, rape, sunflower, peas, soya, barley, etc.) or food plants and flowers. Preferentially, it is possible to choose plants known to contain large

reserves (protein, glucidic and lipidic), in particular cereal plants and oily plants.

5 The hybrid plants obtained by crossing plants according to the invention also form part of the invention.

Another object of the invention is a method of obtaining an Angiosperm plant having improved agronomic or nutritional qualities, comprising the steps consisting of:

10

- transforming at least one Angiosperm plant cell by means of a vector as defined previously;

15

- cultivating the cell thus transformed so as to generate a plant containing in its genome an expression cassette according to the invention.

The transformation of vegetable cells can be achieved by the techniques known to one skilled in the art.

20

It is possible to cite in particular the methods of direct transfer of genes such as direct micro-injection into plant embryoids (Neuhaus et coll. 1997), vacuum infiltration (Bechtold et al. 1993) or electroporation (Chupeau et coll., 1989) or direct precipitation by means of PEG (Schocher et coll., 1986) or the bombardment by gun of particles covered with the plasmidic DNA of interest (Fromm M et al., 1990).

30

It is also possible to infect the plant with a bacterial strain, in particular Agrobacterium. According to one embodiment of the method of the invention, the vegetable cells are transformed by a vector according to the

invention, the said cell host being able to infect the said vegetable cells by allowing the integration, in the genome of the latter, of the nucleotide sequences of interest initially contained in the above-mentioned vector genome. Advantageously, the above-mentioned cell host used is *Agrobacterium tumefaciens*, in particular according to the method described in the article by An et al., (1986), or *Agrobacterium rhizogene*, in particular according to the method described in the article by Guerche et al. (1987).

For example, the transformation of vegetable cells can be achieved by the transfer of the T region of the tumour-inducing extra-chromosome circular plasmid of *Agrobacterium tumefaciens*, using a binary system (Watson et al., 1994). To do this, two vectors are constructed. In one of these vectors the T region has been eliminated by deletion, with exception of the right and left borders, a marker gene being inserted between them to allow selection in the plant cells. The other partner of the binary system is an auxiliary plasmid Ti, a modified plasmid which no longer has any T region but still contains the virulence genes *vir* necessary to the transformation of the vegetable cell.

25

According to a preferred mode, it is possible to use the method described by Ishida et al. (1996) for the transformation of Monocotyledons.

30 According to another protocol, the transformation is achieved according to the method described by Finer et al. (1992) using the tungsten or gold particle gun.

Another object in the invention is the use of the promoter nucleotide sequences referred to previously in molecular constructions intended to improve the agronomic, food or industrial quality of a plant, by acting in particular on  
5 the size of the embryo or of the endosperm and/or its development.

This is because an early specific action on the development of the tissues of the embryo and of the  
10 endosperm can be sought: according to the relative size of one or other tissue, it would be possible to obtain seeds or fruits with a higher starch (large endosperm) and/or oil (large embryo) content, via the use respectively of stimulator genes (hormone of the cellular  
15 cycle for example) or inhibitor genes (toxic protein or transcription inhibitor for example). Endosperms without embryos could also be obtained according to this model, for industrial applications in starch making and semolina processing.

20

By way of example, the use of genes coding for hormones (cytokinins, auxins) of the cell cycle, under the control of the promoters described according to the invention, would make it possible to modify the processes of  
25 cellularisation and, in a correlated fashion, the development of the endosperm in the light of the work of R J Scott (1998).

Action on the accumulation of nutrients in the embryo and  
30 endosperm can also be sought, using for example, as genes of interest, genes coding for transporters of nutrients (sugar in particular), to the interfaces between mother plant/endosperm and endosperm/embryo, or genes coding for

inhibitors of these transports, for a differential accumulation of nutrients in the endosperm or embryo.

5 The invention therefore also relates to methods for  
modifying the agronomic and/nutritional qualities of a  
plant, through an early targeted action on the development  
of the embryo/endosperm, using the transformation of the  
plants with a vector according to the invention. In  
particular, it is concerned with the modification of the  
10 size and/or the development of the embryo/endosperm. It  
also relates to the alteration of the development of the  
embryo, with a view to producing seeds without embryos for  
cereals in particular, presenting an interest for the  
starch and semolina industries.

15

The object of the invention is more precisely the use of  
an expression cassette as defined previously, for  
obtaining a transgenic Angiosperm plant exhibiting  
improved agronomic or nutritional qualities.

20

Advantageously, the transgenic plant obtained can produce  
grains with starch or oil contents which are modified in  
comparison with a non-transformed plant.

25 The invention also concerns the use of the transgenic  
plants obtained according to the invention, or parts of  
these plants in particular seeds, grains and fruits for  
preparing derived products, in particular food products.

30 The products obtained, whether it be seeds with a higher  
oil content, flours of seeds or grains with a higher  
starch or oil content, also come within the scope of the  
invention.

Finally, the object of the invention is any composition for human or animal food prepared from the said products obtained.

5

The following figures and examples illustrate the invention without limiting its scope.

LEGEND TO THE FIGURES

10

- Figure 1 depicts a diagram illustrating the steps of the cloning of the *Esr* promoters.

15

- Figure 2 depicts the restriction map of the plasmid L82/34, comprising in particular the promoter *pEsr1* fused with *Gus*.

20

- Figure 3 depicts the restriction map of the plasmid L124.19, comprising in particular the promoter *pEsr2* fused with *Gus*.

25

- Figure 4 depicts the restriction map of the plasmid L127a5, comprising in particular the promoter *pEsr3* fused with *Gus*.

30

- Figure 5 depicts the restriction map of the plasmid L78a1, comprising in particular the promoter *pEsr1* fused with *lpt*.

- Figure 6 depicts the restriction map of the plasmid L125a2, comprising in particular the promoter *pEsr2* fused with *lpt*.



- Figure 7 depicts the restriction map of the plasmid L77a101, comprising in particular the promoter *pEsr1* fused with *Barnase*.
- 5 - Figure 8 depicts the restriction map of the plasmid L126a3, comprising in particular the promoter *pEsr1* fused with *Barnase*.
- Figure 9 shows a comparison of the sequences of the  
10 promoters of the genes *Esr1*, *Esr2* and *Esr3* (respectively *prEsr1*, *prEsr2* and *prEsr3*, or SEQ ID N° 1, SEQ ID N° 2, and SEQ ID N° 3), the preserved parts being aligned.
- 15 - Figure 10 depicts the restriction map of the plasmid pWP280.
- Figure 11 depicts the restriction maps of the plasmid L129/46, comprising notably the promoter *pEsr2* fused  
20 with the sequence *Esr2* in antisense orientation.

### EXAMPLES

#### EXAMPLE 1:

25

Quantitative expression *Esr1*, 2, 3.

The work by Opsahl-Ferstad et al. (1997) identified by "differential display" a specific amplicon of the  
30 endosperm *Esr1* (access number on the EMBL database: X98495) and isolated by screening complementary genome banks on hybrid line HD5\*HD7 (Barloy et coll. 1989) and line A188 (Gerdes and Tracey, 1993) respectively, of the

corresponding clones. From genome sequences *Esr1g1* (access number on EMBL: X98497) and *Esr2g1* (access number on EMBL: X98499) and *Esr3g2* (access number on EMBL: X99970) in particular, 3 genes *Esr1*, *Esr2* and *Esr3* were  
5 revealed.

The authors of the present invention assessed the relative contributions of expression of each of the genes *Esr* by means of RT-PCR experiments, digestion by restriction  
10 enzymes and quantification according to the methods known to persons skilled in the art, using DAP 7 and DAP 9 (day after pollination) equipment.

Quantification of the different bands identified on  
15 migration gel reveals relative contributions of 18%, 53% and 29% on average, for the transcripts of *Esr1*, *Esr2* and *Esr3* respectively. The promoter of *Esr2* therefore affords the strongest quantitative expression of the gene which it controls.

20

#### EXAMPLE 2:

##### **Isolation and cloning of the promoter sequences**

25 As illustrated in Figure 1, fragments containing the open reading phases of *Esr1*, *Esr2* and *Esr3* (Opsahl et al., 1997) as well as upstream and downstream sequences were sub-cloned in the plasmid pBluescript SK+ (Stratagene) in accordance with the methods described in Sambrook et al.  
30 (1989). The result was the plasmid L23/7 containing a fragment *Sall* of 2.1 kb of  $\lambda$ *Esr1g1* and the plasmid L33/1 containing a fragment *BamHl* of 3.4 kb of  $\lambda$ *Esr2g1*. The plasmid L33/10 containing a fragment *BamHl* of 1.9 kb of

λEsr2g1 and the plasmid L102c24 containing a fragment HindIII of 4.5 kb of λE1-111. XbaI sites situated just upstream of the open reading phase (TCTAGATTCCATG) made it possible to differentiate the putative promoters of the  
5 respective open reading phases. In particular, the fragment SalI/XbaI of 0.53 kb of L23/7 was designated as a putative promoter of Esr1, the fragment HindIII/BamHI of 2.35 kb of L33/1 (upstream part of the promoter) and the fragment BamHI/XbaI of 0.14 kb of L33/10 (downstream part  
10 of the promoter) that of the putative promoter of Esr2, the fragment HindIII/XbaI of 1.71 kb, that of the putative promoter of Esr3 and the fragment XbaI/XbaI of 1.62 kb comprising the putative promoter of Esr4. A functional promoter Esr2 of 2.49 kb was reconstructed from the  
15 fragment HindIII/BamHI of 2.35 kb of L33/1 and from the fragment BamHI/XbaI of 0.14 kb of L33/10, in a base plasmid of the pBSSK+ type (Stratagene). The orientation of the arrows in Figure 1 represents the orientation 5'-3'.

20

**EXAMPLE 3:****Structure of the sequences upstream of the *Esr* genes**

25 Comparisons between the sequences of the regions 5' showed two types of homologies: a highly preserved sequence which corresponds to a proximal sequence of 265 pairs of bases and sequences of retrotransposons in the distal part. As the sequences of retrotransposons are in  
30 different orientations and positions in the three promoters, they do not seem to fulfil a role in the expression of the *Esr* genes. Consequently, the 265 pairs of bases will contain all the *cis* information necessary

for an expression of specific genes of the region surrounding the embryo.

The consensus sequence (SEQ ID N° 7) was obtained after  
5 alignment of the three promoter nucleotide sequences and using Sequencher 3.1 software from Genes Codes Corporation (Ann Arbor, MI 48106).

The degenerated bases are described in the Nomenclature  
10 Committee of the International Union of Biochemistry (1985): Nomenclature for Incomplete Specified Bases in Nucleic Acid Sequences, European Journal of Biochemistry 150: 1-5.

15 In particular,

B = C, G or T but not A

D = A, G or T but not C

20

H = A, C or T but not G

K = G or T

25 M = A or C

N = G, A or C

R = G or A

30

S = C or G

V = A, C or G but not T

W = A or T

X = G, A, T or C

5

and Y = C or T.

A homology is also observed between the proximal regions which extend over approximately 500 pairs of bases between the promoter of *Esr2* and that of *Esr3*, as defined by the sequences SEQ ID N° 5 and N° 6.

The presence of elements acting in *cis* is sought amongst the preserved sequences, the most remarkable being CTACACCA, in tandem just 50 bases upstream of the open reading phase (Figure 9). This sequence is a good candidate for being an element responsible for a tissue-specific gene expression. The first of these repetitions is also placed in the loop of the greatest reversed repetition found in the three promoters. The sequences repeated more than twice are preserved only between the promoters *pEsr2* and *pEsr3*, in the missing region of *Esr1*: for example the sequences ATTCT and TTTTA, each being repeated four times, a potential transcription enhancer in the light of the lowest expression of *Esr1* (Figure 9).

To demonstrate the functionality of the *cis* elements, constructs comprising deleted promoter nucleotide sequences, fused with *GUS*, were prepared.

30

By way of example, two techniques were used to create deletions of the promoter *Esr2*:

- by extensive digestion of 5' to 3' on the fragment HindIII-XbaI by means of the Erase-a-base™ kit from Promega (constructions L140);

- 5 - by PCR amplification of fragments of the promoter (constructions L194).

The plasmids L190 and L194 contain deleted promoter ESR2 fused with a reporter gene Gus and a terminator in accordance with the techniques described in the following example.

For the transformation, the fragments containing the constructs, deleted promoters constructs ESR2 - Gus - ter' were transferred into another plasmid containing the construct "promoter ubiquitin-luciferase-ter", the latter serving as an internal standard for quantifying the Gus activity and correcting the position effect of the insertion of the transgene in the genome on the expression, variable from one transformed plant to another.

The fragments of the promoter ESR2 resulting from these deletions are set out in the following table 1:

Table 1:

Chosen deletion technique	Remaining fragment of the promoter <i>Esr2</i> *
Digestion kit (L140)	985-2493
	1254-2493
	1865-2493
	1874-2493
	1880-2493
	2077-2493
Amplification PCR (L194)	2163-2493
	2275-2493
	2373-2493

- 5 \* the numbering of the promoter *Esr2* is based on the sequence p*Esr2* presented in an annexe (SEQ ID N° 2) which goes from HindIII (AAGCTT or A = position 1) to XbaI (TCTAGA or A = position 2493).
- 10 To demonstrate the functionality of the promoter nucleotide sequences described above, the inventors cloned them upstream of the reporter gene GUS and used the constructs obtained for the transformation of plants.
- 15 In a preferred manner, the deleted promoters *Esr2* were obtained in accordance with the following protocols:
- Firstly, deletions of 5' to 3' were effected using exonuclease III. The plasmid L124/19 containing the promoter of the gene *Esr2* coupled to the gene of the  $\beta$ -glucuronidase described in Example 4.1 was digested by
- 20 HindIII in order to generate an initiation site for the deletions and by PstI to create a protection site against the action of the exonuclease III. The deletions were
- 25 carried out with the Erase-a-base™ (Promega) kit.

Secondly, fragments of the promoter were amplified using the initiator ESRX (5'GGGGTCTAGACTGTGAAGCTATTTTCCA3' (SEQ ID N° 8)) containing the restriction site XbaI (underlined) and ESRH1 (5'GGGGAAGCTTTACATTCTTGCCATAACATA3' (SEQ ID N° 9)), ESRH2 (5'GGGGAAGCTTTTCATCAATAATGCCTCATT3' (SEQ ID N° 10)) or ESRH3 (5'GGGGAAGCTTTAATTTCTTACTTCCTATCT3' (SEQ ID N° 11)) containing the HindIII restriction site (underlined). The amplification products digested by XbaI and HindIII replaced the entire promoter *Esr2* upstream of the gene of the  $\beta$ -glucuronidase in the plasmid L124/19.

The deleted promoters associated with the  $\beta$ -glucuronidase gene were then cloned in a plasmid containing the luciferase gene under the control of the promoter of the rice actin. The latter was obtained by cloning the fragment XhoI/NcoI of the plasmid pAct1-F4 (Mc Elroy D. et al., Mol Gen Genet., 231: 150-160, 1991) corresponding to the promoter and first intron of the rice actin, in a plasmid of the pGP214 type containing the luciferase gene and the terminator of nopaline synthase (Twell D. et al., Development 109, 705-713, 1990), digested by SalI/NcoI. An adaptor containing the restriction sites SalI and NotI, formed in nucleotides 5'GGCCAGTCGACAAAGCGCCGCATGCA3' (SEQ ID N° 12) and 5'TCAGCTGTTTCGCCGCGCT3' (SEQ ID N° 13) was introduced into the plasmid obtained, digested by NotI and PstI (plasmid L210). The fragments SalI/NotI containing the deleted promoters associated with the  $\beta$ -glucuronidase gene were cloned in the plasmid L210 digested by SalI and NotI.

#### EXAMPLE 4:



## Preparation of chimeric constructs

All the constructions can be effected in particular according to the methods described in Sambrook et al. (1989). The adaptors which can be used by way of example for cloning these fragments upstream of the different effecting genes are described in the restriction maps of the corresponding plasmids.

### 4-1 GUS chimeric constructs

The plasmid L23/7 (Esr1) was deleted from a fragment SacI containing undesirable restriction sites. Then a fragment XbaI/EcoRI of 2164 pairs of bases of the plasmid pBl101 (Jefferson et al., 1987) containing a *Gus* gene (coding for the  $\beta$ -glucuronidase but with no promoter) and a terminating sequence *nos*, was introduced. The new plasmid thus formed was then digested by XhoI and the digestion product containing the promoter region associated with the *Gus* gene and positioned upstream of the latter was subcloned in the vector pBCKS+ (Stratagene) so that the promoter is close the hybridisation zone of the initiator T7, thus enabling the plasmid L82/34 to be obtained (Figure 2, Table 2).

According to a similar protocol and with the restriction enzymes indicated in the corresponding figures, it was possible to obtain the plasmids L124/19 (pEsr2-GUS, Figure 3, Table 3) and L127a5 (pEsr3-GUS, Figure 4, Table 4).

It is also possible to use other reporter genes in replacement for GUS, for example GFP (Green Fluorescent

Protein, Siemering KR et al., 1996), to confirm the results obtained with GUS.

According to a protocol similar to that described previously, the fragment HindIII-XbaI of the promoter pEsr2 was fused with the coding sequence for GFP.

Table 2: Characteristics of the plasmid L82/34

Fragment	Position	Reference
pEsr1	741-1272	
Gus	1302-3107	
ter nos	3181-3434	
cat	5878-5223	
pBCKS+	1-740	Stratagene
L23/7 (pEsr1)	741-1272	Opsahl-Ferstad et al., 1997* and this example
pBI101	1273-3436	Jefferson et al., 1987
L23/7	3437-3763	Opsahl-Ferstad et al., 1997 and this example
(upstream)	3764-3769	Stratagene
pBSSK+	3770-6428	Stratagene
pBCKS+		

10

\* the insert corresponds to the fragment Esr1g1 drawn in Figure 4 of Opsahl-Ferstad et al., 1997

Fragment	Position	Reference
pEsr2	689-3175	
Gus	3205-5010	
ter nos	5084-5337	
bla	7441-6584	
pBSSK+	1-674	Stratagene
Linker JFB 34	675-688	this example <sup>1)</sup>
L33/1 (pEsr2')	689-3037	this example**
L33/10 (pEsr2'')	3038-3175	Opsahl-Ferstad et al., 1997 and this example**
pBI101	3176-5339	Jefferson et al., 1987
linker JFB56	5340-5346	this example <sup>2)</sup>
pBSSK+	5347-7566	Stratagene

<sup>1)</sup> adaptor JFB34: 5' TCGACTGCAGCCCA 3' (SEQ ID N° 14)

3' GACGTCGGGTTCGA 5' (SEQ ID N° 15)

[illegible]

3' TGGGCTTAAGCGCCGG 5' (SEQ ID N° 17)

Table 4: Characteristics of the plasmid L127a5

Fragment	Position	Reference
pEsr3	689-2390	
Gus	2420-4225	
ter nos	4229-4552	
bla	6656-5799	
Pbssk+	1-674	Stratagene
Linker JFB 34	675-688	this example
L102c24 (pEsr3)	689-2390	this example
pBI101	2391-4554	Jefferson et al., 1987
linker JFB56	4555-4561	this example
pBSSK+	4562-6781	Stratagene

#### 5 4-2 Chimeric constructs lpt

The lpt gene codes for isopentenyl-transferase, which is an enzyme involved in the synthesis of cytokinine, a phytohormone implicated in vegetable cell growth. The gene sequence was determined by Heidekamp F. et al. (1983). Prior works also showed that this sequence, under the control of a specific promoter of the ovule, made it possible to increase the dry matter content in the fruit, in tomatoes, Martineau B. et al. (1995).

According to the cloning methods described above and with the fragments of nucleic acids and restriction enzymes indicated in the corresponding figures, it was possible to prepare constructs pEsr1-lpt (Figure 5, Table 5) and pEsr2-lpt (Figure 6, Table 6). It is also possible to obtain a construct pEsr3-lpt, according to the same protocol. For preparing these constructs, NcoI (CCATGG) sites straddling the codon ATG of the start of the open reading phase were used instead of the XbaI sites.

Table 5: Characteristics of the plasmid L78a1

Fragment	Position	Reference
pEsr1	310-844	
ipt	846-1565	
ter ipt	1566-	
bla	1850	
	2963-	
	3823	
pUC118	1-231	Boehringer
L23/7 (pEsr1)	232-844	Opsahl-Ferstad et al., 1997 and this example
isolated mutation	845	Zhang et al., 1996
pRZ1	846-1883	Zhang et al., 1995
pUC118	1884-	Boehringer
	4763	

5 Table 6: Characteristics of the plasmid L125a2

Fragment	Position	Reference
pEsr2	689-3183	
ipt	3185-3904	
ter ipt	3905-4189	
bla	6309-5449	
pBSSK+	1-674	Stratagene
Linker JFB 34	675-688	this example
L33/1 (pEsr2')	689-3037	this example
L33/10 (pEsr2'')	3038-3183	Opsahl-Ferstad et al., 1997 and this example
isolated mutation	3184	Zhang et al., 1996
pRZ1	3185-4198	Zhang et al., 1995
adaptor JFB56	4199-4214	this example
pBSSK+	4215-6434	Stratagene

#### 4-3 Barnase chimeric constructs

- 10 The barnase gene codes for an Rnase. This gene was isolated using *Bacillus amyloliquefaciens* (Hartley, 1988). Its use for creating sterile male plants was described in

the application EP 344 029 published by Mariani et al. (1990).

In the context of the invention, the plasmids L77a101  
 5 (pEsrl-barnase) and L126a3 (pEsr2-barnase) described in  
 Figures 7 (Table 7) and 8 (Table 8) were obtained from the  
 plasmid "promoter A6-barnase" described in WO 92/11379, by  
 replacing pA6 with the promoters pEsrl and pEsr2  
 respectively, in accordance with the techniques known to  
 10 persons skilled in the art.

It is also possible to obtain a construct pEsr3-Barnase,  
 in accordance with a similar protocol.

15 Table 7: Characteristics of the plasmid L77a101

Fragment	Position	Reference
pEsrl	80-605	
Barnase	613-945	
ter CaMV	1571-2257	
bla	4324-3467	
pA3	1-28	Scott et al., 1992
L23/7 (pEsrl)	29-605	Opsahl-Ferstad et al., 1997 and this example
pA3	606-4473	
		Scott et al., 1992

Table 8: Characteristics of the plasmid L126a3

Fragment	Position	Reference
pEsr2	43-2529	
Barnase	2537-2869	
ter CaMV	3495-4181	
bla	6248-5391	
pA3	1-28	Scott et al., 1992
linker JFB34	29-42	this example
L33/1 (pEsr2')	43-2391	this example
L33/10	2392-2529	Opsahl-Ferstad et al., 1997 and this example
(pEsr2'')	2530-6397	Scott et al., 1992
pA3		

#### 5 4-4 Chimeric construct antiEsr2

The reconstituted functional promoter *Esr2* (2.49 kb), described in Example 2 and chosen preferentially in the light of the quantitative expression results described in Example 1, was fused with the sequence *Esr2g2* (Opsahl et al., 1997) taken in antisense orientation, itself fused with the terminator *Nos*.

In a preferred manner, the chimeric construct containing the gene *Esr2* in the reverse direction under the control of its own promoter was obtained in accordance with the following protocol:

In a plasmid derived from pJIT30 containing the promoter 35S, a multiple cloning site and the terminating sequence of the cabbage mosaic virus (Guerineau F. et al., Plant Mol Biol, 15: 127-136, 1990), an adaptor containing a *SpeI* site and formed by the oligonucleotides (5'GATCCACTAGTCCCG (SEQ ID N° 18)) and (5'AATTCGGGACTAGTG (SEQ ID N° 19)) was

inserted between the sites BamHI and EcoRI. The fragment EcoRI/SpeI of the plasmid L42 a14 (Opsahl-Ferstad et coll., 1997) was inserted in the plasmid described previously. The construction thus obtained contained the  
5 gene *Esr2* in antisense orientation under the control of the promoter 35S (plasmid L79 b5).

The promoter 35S was eliminated in the plasmid L79 b5 by restriction by SacI and HindIII, and replaced by an  
10 adaptor containing the restriction site HindIII and NotI and formed by the oligonucleotides (5'AAGCTTTTTCGGCCGC (SEQ ID N° 20)) and (5'TCGAGCGGCCGCAAAAAGCTTAGCT (SEQ ID N° 21)). The promoter *Esr2* in the form of a fragment HindIII/NotI of 2.44 kb was introduced into this adaptor.  
15 The construction thus obtained contains the gene *Esr2* in antisense orientation under the control of its own promoter (plasmid L129/46 (cf Figure 11)).

According to a similar protocol, it is possible to obtain  
20 the constructs comprising the promoter *Esr2* fused with the antisense sequences *Esr1* and *Esr3* respectively. It is also possible to obtain the same type of chimeric constructs with the other *Esr* promoters according to the invention.

25

Constructs comprising the constituent promoter 35S fused with the *Esr* antisense sequences described below have also been obtained.

### 30 EXAMPLE 5:

Obtaining transgenic plants (necessity for the stable transformation of maize)



Transient expression experiments using transformation by bombardment of vegetable cells, with chimeric constructs pEsr-GUS and constituent promoter-GUS respectively, did not give results revealing the specificity of expression of the promoters tested: no GUS activity was displayed in the area defined by the Esr cells. The small size of this area and other peculiar particularities could explain the fact that the technique is unsuited under standard conditions to transient expression. By way of example, the constituent promoters tested as a control are the rice actin promoters (McElroy et al., 1992), maize ubiquitin (Christensen et al., 1996), maize Adh (Dennis et al., 1984) and 35S (Odell et al., 1985), gave a blue colouring throughout the endosperm, demonstrating the functionality of the transformation system, but not in the area surrounding the embryo, which confirms the unsuitability of the system for this area.

The transformation aimed at a stable expression therefore became necessary for studying the specificity of expression of the promoters according to the invention.

### 5-1 Particle gun

The method used is based on the use of a particle gun identical to the one described by J. Finer (1992). The target cells are undifferentiated cells in rapid divisions which have preserved suitability for the regeneration of entire plants. This type of cell composes the embryogenic callus (referred to as type II) of maize. These calluses are obtained from immature embryos of the genotype Hill according to the method and on the media described by

Armstrong (Maize Handbook: 1994, M. Freeling, V. Walbot Eds, pp. 665-671). These fragments of the calluses with a surface area of 10 to 20 mm<sup>2</sup> were disposed, 4 hours before bombardment, at the rate of 16 fragments per dish, in the centre of a Petri dish containing a culture medium identical to the initiation medium, with 0.2 M of mannitol + 0.2 M of sorbitol added. The plasmids described in the previous examples and carrying the genes to be introduced are purified on a Qiagen<sup>R</sup> column following the instructions of the manufacturer. They are then precipitated on particles of tungsten (M10) in accordance with the protocol described by Klein (1987). The particles thus coated are projected towards the target cells by means of the gun and in accordance with the protocol described by J. Finer (1992). The dishes of calluses thus bombarded are then sealed by means of Scellofrais<sup>R</sup> and then cultivated in darkness at 27°C. The first planting out took place 24 hours afterwards, and then every fortnight for 3 months on a medium identical to the initiation medium with a selective agent added. After 3 months or sometimes earlier, calluses are obtained whose growth is not inhibited by the selective agent, normally and for the major part composed of cells resulting from the division of a cell which integrated in its genotype one or more copies of the selection gene. The frequency of obtaining such calluses is approximately 0.8 callus per dish bombarded.

These calluses are identified, individualised, amplified and then cultivated so as to regenerate plant germs, modifying the hormonal and osmotic balance of the cells in accordance with the method described by Vain et al. (1989). These plants are then acclimatised in a

greenhouse, where they can be crossed in order to obtain hybrids or self-fertilised.

## 5-2 Transformation by *Agrobacterium*

5

Another transformation technique which can be used in the context of the invention uses *Agrobacterium tumefaciens*, in accordance with the protocol described by Ishida et al. (1996), in particular from immature embryos from 10 days after fertilisation. All the media used are referenced in the reference cited. The transformation begins with a co-culture phase in which the immature embryos of the maize plants are brought into contact for at least 5 minutes with *Agrobacterium tumefaciens* LBA 4404 containing the superbinary vectors. The superbinary plasmid is the result of a homologous recombination between an intermediate vector carrying ADN-T containing the gene of interest and/or the selection marker derived from the plasmids described in the previous examples, and the vector pSB1 of Japan Tobacco (EP 672 752) which contains: the genes *virB* and *virG* of the plasmid pTiBo542 present in the supervirulent strain A281 of *Agrobacterium tumefaciens* (ATCC 37349) and a homologous region found in the intermediate vector allowing this homologous recombination. The embryos are then placed on a medium LSAs for 3 days in darkness and at 25°C. A first selection is effected on the transformed calluses. The embryogenic calluses are transferred onto a medium LSD5 containing phosphinotricine at 5 mg/l and cefotaxime at 250 mg/l (elimination or limitation of the contamination by *Agrobacterium tumefaciens*). This step is carried out 2 weeks in darkness and at 25°C. The second selection step is carried out by the transfer of the embryos which are

developed on an LSD5 medium, on an LSD10 medium (phosphinotricine at 10 mg/l) in the presence of cefotaxime, for 3 weeks under the same conditions as before. The third selection step consists of excising the  
5 type I calluses (fragments of 1 to 2 mm) and transferring them 3 weeks in darkness and at 25°C onto an LSD 10 medium in the presence of cefotaxime.

The regeneration of the plant germs is carried out by  
10 excising the type I calluses which have proliferated and transferring them onto an LSZ medium in the presence of phosphinotricine at 5 mg/l and cefotaxime for 2 weeks at 22°C and under continuous light.

15 The plant germs which have regenerated are transferred onto an RM + G2 medium containing 100 mg/l of Augmentin for 2 weeks at 22°C and under continuous illumination for the development step. The plants obtained are then transferred to the phytotron with a view to their  
20 acclimatisation.

**5-3 Preferred mode for the barnase constructs:  
retransformation of the act-barstar calluses**

25 The barnase chimeric constructs described in Example 3 can be used for conventional transformations according to one or other of the techniques described above.

According to a preferred mode, adapted to the toxic  
30 character of barnase, pretransformed calluses are used for the transformation, containing the gene barstar, which codes for a specific inhibitor of Barnase (Hartley, 1988). This gene serves as "protection" during the process of

regenerating these calluses, which takes place essentially from embryogenesis in maize.

- step a: obtaining a line expressing barstar and a plasmid containing the gene for resistance to hygromycine:

A first transformation step is carried out in accordance with one of the protocols described, with the plasmid pWP280 containing the cassette pActin-intron-Barstar-Nos poly A.

This cassette was obtained according to the following steps: the barnase fragment was amplified with PCR from the plasmid pTG2 (Horovitz et al., 1990) and then subcloned as a fragment XbaI/HindIII in the plasmid pBluescript KS+ (Stratagene) giving the plasmid pWP118.

The barstar gene was then transferred as a fragment XbaI/HincII into a site XbaI/SmaI of the plasmid pW90, derived from the plasmid pJLT30 described by Guerineau et al. (1990) (promoter 35SCaMV replaced by the double promoter 35S and the *polylinker* region between the sites XbaI and EcoRI replaced by the sites SpeI, BamHI, SmaI and PstI).

The region polyA CaMV of the plasmid obtained is replaced by the region nos polyA of pED23 (Dale et al., 1991) forming the plasmid pWP266. Finally, the double promoter region 35S CaMV is replaced by the rice actin promoter and the intron derived from pCOR113 (Mc Elroy et al., 1991) forming the plasmid pWP280 (Figure 10).

The "actin-barstar promoter" plants thus produced are analysed by Northern Blot in order to identify the plants

correctly expressing ARNm coding for Barstar. The plants thus produced supply embryos expressing the Barstar gene, which will be used for producing type II calluses according to known techniques: putting the embryos in  
5 culture on a medium inducing callogenesis and replanting on a selective medium containing hygromycin.

- step b: transformation of these calluses with the barnase chimeric construct:

10

The act-barstar calluses obtained at the previous step are then bombarded according to the technique described at point 5-1 with the "Esr-barnase promoter" construct previously described with a plasmid conferring resistance  
15 to Basta (pDM302, Mc Elroy et al., 1991). The two genes are then separated into the descendants by segregation, in order to see the effect of the single promoter construct Esr-barnase.

20 Better results, particularly with regard to the effectiveness of transformation and the number of plants regenerated, were obtained according to this preferred mode, in comparison with the conventional technique which aims to transform the calluses directly by means of the  
25 "Esr-barnase" constructs.

#### EXAMPLE 6

Demonstration of the functionality of the promoter  
30 sequences (the case of GUS constructs)

In order to detect the  $\beta$ -glucuronidase activity, the maize seeds issuing from plants transformed by the particle gun

5

10

15

20

BIBLIOGRAPHY

- 5    - Armstrong (1994), *Maize Handbook*, Freeling, M., Walbot,  
V. Eds, 665-671.
- Barloy, D. et coll. (1989), *Maydica*, 34, 303-308.
- 10   - Becker, H.A. et al. (1999), *Domains of gene expression*  
*in developing endosperm*, 361-375.
- Breton, C. et al. (1995), *Plant Mol. Biol.*, 27, 105-113.
- 15   - Christensen et al. (1996), *Transgenic Res.*, 5: 213.
- Clark, J.K. and Sheridan, W.F. (1986), *J. Heredity*, 77,  
83-92.
- 20   - Dale et al. (1990), *Gene*, 91: 79-85.
- Davis, R.W. et coll. (1990), *Can. J. Bot.*, 68, 471-479.
- 25   - Dennis (1884), *Nucl. Ac. Res.*, 12: 3983-4000.
- Devic et al. (1997), *Plant Physiol. Biochem.*, 35: 35(4):  
331-339.
- Finer, J. (1992), *Plant Cell Report*, 11: 323-328.
- 30   - Gerdes, J.T. and Tracy, W.F. (1993), *Crop Sci.*, 33, 334-  
337.
- Guerche et al. (1987), *Mol. Gen. Genet.*, 206: 382.



- Guerineau et al. (1990), *Plant. Mol. Biol.*, 15: 127-136.
- Hartley et al. (1988), *J. Mol. Biol.*, 202, 913-915.
- 5 - Heidekamp, F. et al. (1983), *Nucl Acids Res*, 11, 6211-6223.
- Horovitz et al. (1990), *J. Mol. Biol.*, 216: 1031-1044.
- 10 - Hu et al. (1995), *Molecular and General Genetics*, 248: 471-480.
- Hueros, G. et al. (1995), *Plant Cell*, 7, 747-757.
- 15 - Ishida et al. (1996), *Nature Biotechnology*, 14: 745-750.
- Jefferson et al. (1987), *Plant Molecular Biology Reporter*, 5(4): 387-405.
- 20 - Klein (1987), *Nature*, 327: 70-73.
- Kowles, R.V. and Phillips, R.L. (1988), *Int. Rev. Cytol.*, 112, 97-136.
- 25 - Kyle, D.J. and Styles, E.D. (1977), *Planta*, 137, 185-193.
- Liang, P. and Pardee, A.B. (1992), *Science*, 257, 967-971.
- 30 - Lopes, M.A. and Larkins, B.A. (1993), *Plant Cell*, 5, 1383-1399.

- Mariani et al. (1990), *Nature*, 347, 737-741.
- Mc Elroy et al. (1991), *Mol. Gen. Genet.*, 231: 150-160.
- 5 - McElroy et al., *Plant Cell*, 2: 163-171, 1990.
- Odell et al. (1985), *Nature*, 313: 810-812.
- 10 - Opsahl-Ferstad, H.D. et al. (1997), *The Plant J.*, 12, 235-246.
- Poole et al. (1985), *Cell*, 40: 37-43.
- 15 - Sambrook et al. (1989), *Molecular Cloning - A laboratory manual*, Cold Spring Harbor Laboratory Press.
- Schel, J.H.N. et coll. (1984), *Can. J. Bot.*, 62, 2842-2856.
- 20 - Scott et al. (1992), patent application WO 92/11 379.
- Siemering, K.R. et al. (1996), *Current Biology*, 6, 1653-1663.
- 25 - Twell, D. et al., *Development*, 109, 705-713, 1990.
- Vain et al. (1989), *Plant Cell Tissue and Organ Culture*, 18: 143-151.
- 30 - Xu, J. et al. (1995), *Plant Physiol.*, 108, 1293-1294.

- Zhang et al. (1995), The effect of auxin on cytokinin levels and metabolism in transgenic tobacco tissue an *ipt* gene, *Planta*, 196: 84-94.
- 5 - Zhang et al. (1996), Expression of the isopentenyl transferase gene is regulated by auxin in transgenic tobacco tissues, *Transgenic Res.*, 5: 57-65.

CLAIMS

1. An isolated promoter nucleotide sequence allowing an expression of the coding sequences to which it is bound;  
5 said expression being i) specific to the region of the endosperm surrounding the embryo in the seeds of the angiosperms and ii) intervening in particular in the early stages of development of the endosperm.
- 10 2. The promoter nucleotide sequence according to Claim 1, isolated from cereals, in particular maize.
3. The promoter nucleotide sequence according to either one of Claims 1 or 2, comprising a sequence selected from  
15 the group consisting of sequence SEQ ID N° 1, N° 2, N° 3, N° 4, N° 5, N° 6 or N° 7, and any sequence which is a homologue of these.
4. The promoter nucleotide sequence according to any one  
20 of the preceding claims, also comprising a regulator element in *cis* defined by the pattern CTACACCA, preferably repeated in tandem.
5. An expression cassette comprising a promoter  
25 nucleotide sequence according to any one of the preceding claims, operatively bound to at least one gene of interest.
6. Expression cassette according to Claim 5, in which the  
30 gene of interest codes for a protein selected from the group consisting of a protein involved in the development of the embryo and/or of the endosperm, the cell growth,

the metabolism of the sugars or that of the fatty acids, a toxic protein, and a transcription inhibiting protein.

7. An expression cassette according to either one of  
5 Claims 5 or 6, in which the gene of interest codes for a first protein chosen from amongst barnase or isopentenyltransferase.

8. An expression vector containing an expression cassette  
10 according to any one of Claims 5 to 7.

9. An angiosperm plant host cell, particularly cereal, transformed by a vector according to Claim 8.

10. A transgenic plant or part of a transgenic plant, in  
15 particular fruit, seed, grain or pollen, generated from a cell according to Claim 9.

11. The plant or part of a plant according to Claim 10,  
20 wherein said plant or part of plant is a cereal or oily plant, selected in particular from the group consisting of maize, wheat, rape and sunflower, preferentially maize.

12. A hybrid transgenic plant obtained by crossing plants  
25 as defined in either one of Claims 10 or 11.

13. A method of obtaining an angiosperm plant having improved agronomic or nutritional qualities, comprising the steps consisting of:

30

- transforming at least one angiosperm plant cell by means of a vector according to Claim 8;

- cultivating the cell thus transformed so as to generate a plant containing in its genome an expression cassette according to any one of Claims 5 to 7.

5 14. Use of an expression cassette as defined in any one of Claims 5 to 7, for obtaining a transgenic angiosperm plant exhibiting improved agronomic or nutritional qualities.

10 15. The use according to Claim 14, for obtaining a transgenic plant producing seeds with starch or oil contents modified compared with a non-transformed plant.

15 16. Use of a plant or part of a plant, in particular a seed, grain or fruit, as defined in any one of Claims 10 to 12, for the preparation of derived products, notably food products.







Fig. 11

Plasmid

5

Promoter of Esr2 gene

Codified sequence of Esr2 gene

10 Terminator

# LIST OF SEQUENCES

- 5 Specific promoters of the endosperm of vegetable seeds

Pages 4-7

Artificial sequence

5

Description of the artificial sequence: oligonucleotide

etc.

10

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION  
EN MATIÈRE DE BREVETS (PCT)

(19) Organisation Mondiale de la Propriété  
Intellectuelle  
Bureau international



(43) Date de la publication internationale  
12 avril 2001 (12.04.2001)

PCT

(10) Numéro de publication internationale  
WO 01/25439 A1

(51) Classification internationale des brevets<sup>7</sup>: C12N 15/29.  
15/82, A01H 5/00

(74) Mandataire: JACOBSON, Claude; Cabinet Lavoix, 2,  
place d'Estienne d'Orves, F-75441 Paris Cedex 09 (FR).

(21) Numéro de la demande internationale:  
PCT/FR00/02596

(81) États désignés (*national*): AE, AG, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) Date de dépôt international:  
19 septembre 2000 (19.09.2000)

(25) Langue de dépôt: français

(26) Langue de publication: français

(30) Données relatives à la priorité:  
99/12305 1 octobre 1999 (01.10.1999) FR

(84) États désignés (*régional*): brevet ARIPO (GH, GM, KE,  
LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), brevet eurasien  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevet européen  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), brevet OAPI (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Déposant (*pour tous les États désignés sauf US*): BIO-  
GEMMA [FR/FR]; 1, rue Edouard-Colonne, F-75001  
Paris (FR).

**Publiée:**

— Avec rapport de recherche internationale.

(72) Inventeurs; et

(75) Inventeurs/Déposants (*pour US seulement*): BONELLO,  
Jean-François [FR/FR]; 9, rue J. Monet, F-77600 Bussy  
St Georges (FR). ROGOWSKY, Peter [GE/FR]; 31, rue  
André Bollier, F-69007 Lyon (FR). PEREZ, Pascual  
[FR/FR]; 17, chemin de la Pradelle, Varennes, F-63450  
Chanonat (FR).

En ce qui concerne les codes à deux lettres et autres abrévia-  
tions, se référer aux "Notes explicatives relatives aux codes et  
abréviations" figurant au début de chaque numéro ordinaire de  
la Gazette du PCT.

(54) Title: PLANT SEED ENDOSPERM-SPECIFIC PROMOTER


(54) Titre: PROMOTEURS SPECIFIQUES DE L'ALBUMEN DES GRAINES DE VEGETAUX

(57) Abstract: The invention concerns promoter nucleotide sequences enabling expression of encoding sequences whereto they can be bound, which is specific of the endosperm region enclosing the embryo of seeds of Angiosperms and which intervene in particular in the early stages of endosperm development, and their use for agronomic or nutritional improvement of plants.


(57) Abrégé: Cette invention concerne des séquences nucléotidiques promotrices permettant une expression des séquences codantes auxquelles elles peuvent être liées, qui est spécifique de la région de l'albumen entourant l'embryon dans les graines des Angiospermes et qui intervient en particulier dans les stades précoces du développement de l'albumen, ainsi que leur utilisation pour l'amélioration agronomique ou nutritionnelle des plantes.

WO 01/25439 A1


1/11



**FIG. 1**




**FIG.2**



**FIG. 3**


4/11



**FIG.4**




5/11



**FIG.5**


55	Pvu II
231	EcoR I
239	EcoR V
243	Hind.III
250	Cla I
258	Sal I
269	Stu I
304	Xho I
305	Sac I
588	Spe I
836	Xba I
844	Nco I
1014	Hlu I
1137	BamH I
1288	Pst I
1357	Cla I
1365	EcoR V
1367	Cla I
1853	BamH I
1859	Xba I
1865	Sal I
1875	Pst I
1881	Sph I
1883	Hind III
1978	Pvu II
2009	Pvu I
3381	Pvu I

503 Pvu I  
532 Pvu I  
557 Kpn I  
583 Apa I  
608 Xho I  
634 Sal I  
660 Pst I  
686 Hind III  
712 Sph I  
738 Sph I  
764 BatX I  
790 Sph I  
816 EcoR V  
842 Cla I  
868 Cla I  
894 Kpn I  
920 Cla I  
946 Nco I  
972 Sac I  
998 BamH I  
1024 Cla I  
1050 Xba I  
1076 Nco I  
1102 Mlu I  
1128 BamH I  
1154 Pst I  
1180 Cla I  
1206 EcoR V  
1232 Cla I  
1258 BamH I  
1284 Xba I  
1310 EcoR I  
1336 Not I  
1362 Sac I  
1388 BatX I  
1414 Sac I  
1440 Pvu I  
1466 Pvu I  
1492



**FIG.6**

5	Sac I
11	Kpn I
17	Apa I
22	Xho I
28	Sal I
39	Stu I
74	Xho I
75	Sac I
358	Spe I
605	Xba I
611	Nco I
806	Sma I
1047	BamH I
1065	Pst I
1094	Pvu II
1362	Pvu II
1492	Hind III
1499	Cla I
1517	Pst I
1519	EcoR I
1745	Bgl II
1765	Bgl II
2217	Bgl II
2235	Spe I
2269	Sph I
2273	EcoR V
2276	Xho I
2280	Bgl II
2466	Pvu II
3907	Pvu I




**FIG. 7**



**FIG. 8**


9/11



**FIG.9**


→ Repeat CTACACC in tandem  
→ Repeat TTTTA → Repeat ATTCT

10/11



**FIG.10**

11/11



Promoter or Es.2 gene  
 Codified sequence for Esr2 gene  
 Terminator Ca MV 35 S

**FIG.11**

Ref. \_\_\_\_\_

# COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PLANT SEED ENDOSPERM-SPECIFIC PROMOTERS

the specification of which: *(check one)*

## REGULAR OR DESIGN APPLICATION

- ☐ is attached hereto.
- ☐ was filed on \_\_\_\_\_ as application Serial No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

## PCT FILED APPLICATION ENTERING NATIONAL STAGE

- ☒ was described and claimed in International application No. PCT/FR0002596 filed on 19/09/2000 and as amended on \_\_\_\_\_ (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

## PRIORITY CLAIM

I hereby claim foreign priority benefits under 35 USC 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

## PRIOR FOREIGN APPLICATION(S)

Country	Application Number	Date of Filing (day, month, year)	Priority Claimed
FRANCE	9912305	01/10/99	YES

*(Complete this part only if this is a continuing application.)*

I hereby claim the benefit under 35 USC 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT-international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status--patented, pending, abandoned)



POWER OF ATTORNEY

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from \_\_\_\_\_ as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

As a named inventor, I hereby appoint the registered patent attorneys represented by Customer No. 000466 to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, including: Robert J. PATCH, Reg. No. 17,355, Andrew J. PATCH, Reg. No. 32,925, Robert F. HARGEST, Reg. No. 25,590, Benoît CASTEL, Reg. No. 35,041, Eric JENSEN, Reg. No. 37,855, Thomas W. PERKINS, Reg. No. 33,027, and Roland E. LONG, Jr., Reg. No. 41,949,

c/o YOUNG & THOMPSON,  
Second Floor,  
745 South 23rd Street,  
Arlington, Virginia 22202.



00466  
PATENT, TRADEMARK OFFICE

Address all telephone calls to Young & Thompson at 703/521-2297. Telefax: 703/685-0573.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00  
Full name of sole or first inventor: Jean-François BONELLO  
(given name, family name)

Inventor's signature [Signature] Date 25/03/02  
Residence: 9 Rue J. Monet - 77600 BUSSY ST GEORGES - FRANCE Citizenship: French  
FRX

Post Office Address: The same as above

2-00  
Full name of second joint inventor, if any: Peter ROGOWSKY  
(given name, family name)

Inventor's signature [Signature] Date 25/03/02  
Residence: 31 Rue André Bollier - 69007 LYON - FRANCE Citizenship: German  
FRX

Post Office Address: The same as above

3-00  
Full name of third joint inventor, if any: Pascual PEREZ  
(given name, family name)

Inventor's signature [Signature] Date 25/03/02  
Residence: 17 Chemin de la Pradelle VARENNES - 63450 CHANONAT Citizenship: French  
FRX

Post Office Address: The same as above

Full name of fourth joint inventor:  
(given name, family name)

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_  
Citizenship: \_\_\_\_\_

Residence: \_\_\_\_\_

## LISTE DE SEQUENCES

&lt;110&gt; Biogemma

&lt;120&gt; Promoteurs spécifiques de l'albumen des graines de végétaux

&lt;130&gt; BFF 99/496ext

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 21

&lt;170&gt; PatentIn Ver.. 2.1

&lt;210&gt; 1

&lt;211&gt; 531

&lt;212&gt; ADN

&lt;213&gt; Zea mays

&lt;400&gt; 1

```

gatcattaag gactaagcag tctttttccc tttcggcttg catcatcttt agtcttcac 60
actattataa gccgaagcta ttaccccttg gctatagctt cgggtgttcat ctttattatc 120
ttcggactat gtcttcacct tgtatacctt tgtcttgggg gaaaaccttc atcctgaagc 180
cgaagctccc tgtaataatt catatcatgc taaaaataaa tggtcagtcg tgtttttgag 240
gaccttcgga agaggaaggc cccccaacaa gacgattaac tagtattgtc tcaactgcatt 300
gttttttttg cacttcacat ataatgcctc aatagcatac ttcatttttag gaactttatt 360
aaaactgtct taaaataggg ccaagtcata aattcattca aagtgactct tcattttcta 420
cttcctatct ttgggtggtt tgtatatata tatgttcacg gttgagtgat gttcctacac 480
cactacacca cacgttagat atatatacag aaaatagctt cactatctag a 531

```

&lt;210&gt; 2

&lt;211&gt; 2493

&lt;212&gt; ADN

&lt;213&gt; Zea mays

&lt;400&gt; 2

```

aagcttttcc ggtgatgaag cacctgtaat acttaacagc atgctgaaaa caaatagtta 60
gctgtgtttt tgaggacctt cggaagatga aggcccccaa cacatcccat gcatcaagtc 120
cccatgactt gcaaaaaagc aaattttatc aaaattttctc ataaaaacact tgaaaaacatt 180
tctctttttg aaaagtgtag agcactagca actgtctact aaaaagggtc ccaaattttct 240
gggtataaca atcgcatggg aaataacaca aaggaaaatcc tactaagagc agtaattttg 300
ctaaaaaat agtgagcatt ttaatgtaat agggaaatagg agcatgcaat acttgtgttc 360
tttcagggtt ttgatgtcct caaaagtgtg cccccctggg gcagttgcaa cactcaaaat 420
ctactcgtat acataaagaa acatgggcac aaaataagaa acaataactca aattatgaaa 480
aagggtcaaaa tggctctata attattgtag acatttttaga atttatttta gacccaaaacc 540
atttaaatat ggttttaaat gaggtagata ttaatattta ttcagtttat agttattttg 600
gacatttatt tacttaacta taacttctag ggttttaaaa gtaaattttg ggtccctagt 660
tggaactagc tcagattgct ggttgatttc cataaaagtc gaggttcctt tagcaaaaaat 720
ccacggtgaa caagggggag atagggtgtg accgatatct ctaaaatttg atcgttggac 780
ggcacatgga tgtctcagat taaatgggtg atgtgcaagc gacgcgcaca cgatggagga 840
atggcttcac gacgggtggc tactagagct ggctacgtca accaatggag ggctcgggtc 900
agggtcaaat ttgttgccaa gccactgtgg ctacacgatga gtcgattgag cacatatcaa 960
gggtcagggg caaccagagg ggcaagatcg atgggtgcagt ggtgttctcg atggaagggg 1020
aaacttcggt gagcaattca agatttccta tcatgtgacc gggtcagggg atgggcgcac 1080
gggggtttgt accttctggt gcacatcatg ttgctgtatc gatgtcaagg gagcattagg 1140
gttcacgagt cagcgatgac gggcatgggt ggacttgtgt caccatgggt cgatcaacta 1200

```

WO 01/25439

PCT/FR00/02596

2

```

gggacgatag agctctatga agtttcacaa ctctctcaca ctctagggat catgggtgaca 1260
aaggtgggga ggacggggcg tctctagtga ggggtggaatg cagttctgtc acgtggggaat 1320
agtggcggca tcgcttgtaa tgaataaaaag gtgcttgggg ggctgggaag tgcaatatga 1380
gggaagtagt tgggtcgggg atgttccttt tataagggag caccattgat taatggaaga 1440
caatgacaca aaggggtggt cgacagttta aagctcgaat gctgctaggg gtgctcaagg 1500
ttaaagatc aggcatacagg gaggaaggc agggataaaa tttctttact ccagttgtgg 1560
ggtgatggg acaagggtag tgctcaagca agggaggcg agttcagcgc agagatgcct 1620
gttgtagacac atggggggg ggaattgga ggttggggtt gaccaggtga cgttatggcg 1680
tgaccagag aagagacca ctgatggga aaaaagggtgc caacaggtgg ggaccaagg 1740
gtcagtgact caccgtgaca tgttattgga aagttacgtc cggaatggtt tgggctgag 1800
tgatctagge tggctcgggc actgtgctga tcttttaatt tctccattcc caatttaagt 1860
tgaattttta attcaaatca aatgactcca aatctctcca aaattacca aatatagaat 1920
atttagatga atatgttggg ggagtttggg ctccgctttt ggtagtatg tttgtataaa 1980
aataatttct ctcttttgt cacttccaat attgacttaa atttttatgt agcaatgcc 2040
acttttttta gtagtggtgc acttatagca caaaaactat atccattttc taatagtcct 2100
tgaaatccac attctatttt tagccattct tcaaaattgg cacaaaacta ggaaaattta 2160
atacattctt gccataacat attctagtgc aaatgttaac tagattgctc aatattagca 2220
aacttctttt gtaagattca ttaatatgac tacattgcat acttttttag aagttcatca 2280
ataatgcctc attagcattc ttcattttag gaacttgatt aaaaccgcct taaaatagca 2340
ccaagtgcac gatcatttta aaggtgattc ttaatttctt acttcctatc tttgggtggc 2400
tatgtttata tatgtgtggg tgggtgaatg atgttctac accactacac cacacgttgg 2460
acatatatat ggaaaatagc ttcacagtct aga 2493

```

&lt;210&gt; 3

&lt;211&gt; 1708

&lt;212&gt; ADN

&lt;213&gt; Zea mays

&lt;400&gt; 3

```

aagcttagaa attttaaaaa aagccaggca agcgttggtg tgcaaagagc taaaaattag 60
gaagacaaga gaacacggca agaaagcatg ctaaatgtgc tcgcggtgcg ttcttattta 120
tacgtccaat acgttgcaag tggtagggcc ccactgtgca ttgactattg ctattctagc 180
aaaggaagg tgttttcgg accttcggct taaggccttc gtccatatcg caatctgaat 240
ttatcattct aacaaattaa tattgtgagg ggctactgtt gggggccttc gacttccgaa 300
ggtcctcaaa aactggttta acagtgtttc tggagtataa tgcataaaca ggtatcttcg 360
ggtttggatc agaactacaa catgaagagg cacaaagaac acgaagggtg gcgcagagcc 420
gaagctcacg tgtaggagag cttcggcacg acagcagaaa aagggaaaccg acttaaaagg 480
aaaggctatt cagacctcga tggatttcta taggtcatta gcaaatgtaa agggcatgaa 540
tgtaatttta catgggctgt gtccttgctt ataaatagat gaacagtact ctgtagtctg 600
tcacgctgac ttggcattcg ctttttgcat cagcgttgta cccttgcttt ccttcaaacc 660
gaaggtagat ctataatttg ttattgtgtt attgtggata tggtaatgca aataaaaaata 720
agttgatgat aatgtttata ttatttttcg tatttcatat atgaattctt cctcatcatt 780
tattgtgctt acgaagggtt ttcttcaaaa atctttgtcc ggaattcatt atatccgaag 840
ggaaataatg tctcgaaggc cgaaggactt tgatatttaa cacttttcat gttgccttgt 900
tcttgactct tagcatttga gaacaagtc ccaacagctc ctaagctctt ctttgaagaa 960
acaactacta gatgaagttt ctccaaaagt acgtccattg aatggagtaa agagtcattt 1020
gacctctcgg aataaaaatta aaatgagaat aagtaagaat aaaacacctc tattatcaaa 1080
tctaggccat acaaacattg ggtattacta aaaaatagct aatgccatct ttcaacattt 1140
ggaagttaaa accaaccaat cctcactcat tcccaagaaa tattggatca tatttaacat 1200
tttggtgcac ttacaaaaat ggcttaattct tttatgcggc aatgccaaac ttttttagca 1260
gggtgccact tgtaacatga aaactataac tattttcaaa tagtaccttg aaattcgcat 1320
tctattttta tgcatcttcc aaaattgaca caaattaaac taggagaatt caatacatct 1380
ttgccataac atattctaatt gcaaatatta agtagattgc tcaacatcgg tacacatctt 1440
ttgcaagatt aattagattt gtctcactac attctttgtt ttagcagttc atcaataatg 1500
cctcaatagc atacttcatt ttaggaactt ttgaaaaatt gtcttaaaat agggccaagt 1560
cacaaatcca cttcaaagggt gactcttcat ttcttacttc ctatctttgc ttgtttttgt 1620
atatatatgt gtggatggtt gagtgatgtt cctacaccac tacaccacac cttagacaca 1680
tatatggaaa atagcttcac tgtctaga 1708

```

WO 01/25439

PCT/FR00/02596

3

<210> 4  
 <211> 1232  
 <212> ADN  
 <213> Zea mays

<400> 4  
 tagttcatgc aaaagtagtg agtggtttata cacctatgcc aatgaataac ctctaactac 60  
 cctcatgtac tggcctgggtg tttgggtaaac atgaagcaat aatttcctct tatcaaaata 120  
 cgggtctcaa gctgcatgtg aaaaataata aatatttttt tgaagtgaat gaaaaatgat 180  
 aaatatgaaa cagtaaatct ttccgttgaa aaagtacatc tctattatta acgataacct 240  
 atatatcaat ctacaatgcg ctcatctgca tctcgatgca tactttcatc attttatgaa 300  
 tgtacttttaa tgataagaag gattagaatg ttcttggttt cctcttattc ttaccttttt 360  
 caaaattatc agtttccaat gtctgaatat gcaatgcatt ataaacccta gtcagcatat 420  
 atcaagtcca tatataatgc tatatgttta agaactgggt ctgagtatgt ctactcaaca 480  
 tatttttttag ctattggatc gagcagttta gtaaaggtaa actacattta tctatcttca 540  
 agttgtattt tcccaccctt aaattatgaa agggagtaac gctccactcc aactggtgaa 600  
 agggaacaaa tttgggtctcc ggactgattt cattgggtgg tctctatttt ttaaaacaac 660  
 aaaaaaacat atttggtctc tgaaaattga taattaatta atcataaatt aggaaaaaaa 720  
 ctatatgaaa ctagttatag ttttcttcta aaattattgt ctgtctgttg gtgctctagt 780  
 tatagagtta taacatgaaa actatagcca ttttcaaata gtgccttgaa attcattttt 840  
 gtttagccat tcttcaaaat tgccaccaa ccaggagaat ttattaataa attcacgcca 900  
 taacatattc tagtccaaat gtttaagtga ttgctcaata tcattatact tcttttggtg 960  
 gattcattag tactgccttg ttgcatactt tgtttttagca gttcatcaat aatgcttcac 1020  
 tagcataatt catgttagga acttgattaa aactgcctta agaacatggc aaagtgataa 1080  
 atccacttca aaggcaatta ttaatttctt acttctatc tttgggtggt tttgtatata 1140  
 tgtgtgtggg tgggtgagtg atgcacacat ttctctacac cactacatca caccttggac 1200  
 atatatgtga aaaaatagct tcgcagtcta ga 1232

<210> 5  
 <211> 499  
 <212> ADN  
 <213> Zea mays

<400> 5  
 ttttgtcact tccaatattg acttaaatct ttatgttagca atgccaaact tttttagtag 60  
 tgtgccactt atagcacaaa aactatatcc attttcta atgccttgaa atccacattc 120  
 tatttttagc cattcttcaa aattggcaca aaactaggaa aatttaatac attcttgcca 180  
 taacatattc tagtgcaaat gtttaactaga ttgctcaata ttagcaaact tcttttgtaa 240  
 gattcattaa tattgttaca ttgcatactt ttttagaagt tcatcaataa tgcctcatta 300  
 gcatacttca ttttaggaac ttgattaaaa ccgccttaaa atagagccaa gtgacggatc 360  
 catttaaagg tgattcttaa tttcttactt cctatctttg gtggcttatg tttatatatg 420  
 tgtgggtggg tgaatgatgt tctacacca ctacaccaca cgttggacat atatatggaa 480  
 aatagcttca cagtctaga 499

<210> 6  
 <211> 507  
 <212> ADN  
 <213> Zea mays

<400> 6  
 ttgtgtcact tacaaaaatg gcttaatctt ttatgcggca atgccaaact tttttagcag 60  
 ggtgccactt gtaacatgaa aactataact attttcaaat agtaccttga aattcgcat 120  
 ctatttttat gcattcttca aaattgacac aaattaaact aggagaattc aatacattct 180  
 tgccataaca tatttctaag caaatattaa gtagattgct caacatcggt acacatcttt 240  
 tggacgatta attagtattg tctcactaca ttctttgttt tagcagttca tcaataatgc 300

WO 01/25439

PCT/FR00/02596

4

```

ctcaatagca tacttcattt taggaacttt atgaaaattg tcttaaaata gggccaagtc 360
acaaatccac ttcaaagggtg actcttcatt tcttacttcc tatctttgct tgtttttgta 420
tatatatgtg tggatgggtg agtgatgttc ctacaccact acaccacacc ttagacacat 480
atatggaaaa tagcttcact gtctaga 507

```

<210> 7  
 <211> 265  
 <212> ADN  
 <213> Zea mays

```

<400> 7
namgattmay tartattggy wcaytcatw sntnttttr gmasttcato aataatgcct 60
cawtagcata cttcatttta ggaacttkat kaaaayygyt ttaaaatagr gccaagtsay 120
rratycantt yaaagntgay tcttmatttc ttacttccta tctttgstkg yttwngtwta 180
tatatrtgtk srtgggtgar tgatgttctt acaccactac accacacstt rgayayatat 240
ayrgaaaata gcttcacwrt ctaga 265

```

<210> 8  
 <211> 28  
 <212> ADN  
 <213> Séquence artificielle

<220>  
 <223> Description de la séquence  
 artificielle:oligonucléotide

```

<400> 8
gggggtctaga ctgtgaagct attttcca 28

```

<210> 9  
 <211> 30  
 <212> ADN  
 <213> Séquence artificielle

<220>  
 <223> Description de la séquence  
 artificielle:oligonucléotide

```

<400> 9
ggggaagctt tacattcttg ccataacata 30

```

<210> 10  
 <211> 30  
 <212> ADN  
 <213> Séquence artificielle

<220>  
 <223> Description de la séquence  
 artificielle:oligonucléotide

```

<400> 10
ggggaagctt ttcataata atgcctcatt 30

```

<210> 11

<211> 30  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 11  
ggggaagctt taatttctta cttcctatct 30

<210> 12  
<211> 27  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 12  
ggccagtcga caaagcggcc gcatgca 27

<210> 13  
<211> 19  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 13  
tcagctgttt cgccggcgt 19

<210> 14  
<211> 14  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 14  
tcgactgcag ccca 14

<210> 15  
<211> 14  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 15  
gacgtcgggt tcga

14

<210> 16  
<211> 16  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 16  
ctagacccga attcgc

16

<210> 17  
<211> 16  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 17  
tgggcttaag cgccgg

16

<210> 18  
<211> 15  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 18  
gatccactag tcccg

15

<210> 19  
<211> 15  
<212> ADN  
<213> Séquence artificielle

<220>  
<223> Description de la séquence  
artificielle:oligonucléotide

<400> 19  
aattcgggac tagtg

15

<210> 20  
<211> 17

WO 01/25439

PCT/FR00/02596

7

&lt;212&gt; ADN

&lt;213&gt; Séquence artificielle

&lt;220&gt;

<223> Description de la séquence  
artificielle:oligonucléotide

&lt;400&gt; 20

aagctttttg cggccgc

17

&lt;210&gt; 21

&lt;211&gt; 25

&lt;212&gt; ADN

&lt;213&gt; Séquence artificielle

&lt;220&gt;

<223> Description de la séquence  
artificielle:oligonucléotide

&lt;400&gt; 21

tcgagcggcc gcaaaaagct tagct

25